<SEC-DOCUMENT>0001047469-17-005543.txt : 20170905
<SEC-HEADER>0001047469-17-005543.hdr.sgml : 20170904
<ACCEPTANCE-DATETIME>20170905171540
ACCESSION NUMBER:		0001047469-17-005543
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20170905
DATE AS OF CHANGE:		20170905

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INSMED Inc
		CENTRAL INDEX KEY:			0001104506
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				541972729
		STATE OF INCORPORATION:			VA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-218118
		FILM NUMBER:		171069532

	BUSINESS ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807
		BUSINESS PHONE:		908-977-9900

	MAIL ADDRESS:	
		STREET 1:		10 FINDERNE AVENUE
		STREET 2:		BUILDING 10
		CITY:			BRIDGEWATER
		STATE:			NJ
		ZIP:			08807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INSMED INC
		DATE OF NAME CHANGE:	20000128
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2233170z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg49701_prospectus">  Prospectus</A> <BR>
<A HREF="#dq49701_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333-218118  </B></FONT></P>

<P style="font-family:arial;"><FONT COLOR="#FF4040" SIZE=2><B>The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has become
effective by rule of the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting
offers to buy these securities, in any state or other jurisdiction where the offer or sale is not permitted.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT COLOR="#FF4040" SIZE=2><B>SUBJECT TO COMPLETION, DATED SEPTEMBER&nbsp;5, 2017</B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><B> PRELIMINARY PROSPECTUS SUPPLEMENT<BR>  </B></FONT><FONT SIZE=2>(To Prospectus dated May&nbsp;19, 2017) </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>$250,000,000 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g839396.jpg" ALT="LOGO" WIDTH="249" HEIGHT="88">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>Common Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="18%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are offering up to $250,000,000 of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on the Nasdaq Global Select Market under the symbol "INSM". The last reported sale price of our common stock on the Nasdaq Global Select Market on
September&nbsp;5, 2017 was $26.99 per share. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described under the heading "Risk Factors" beginning on
page&nbsp;S-8 of this prospectus supplement before buying shares of our common stock.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Total<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions<SUP>(1)</SUP></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Proceeds, before expenses, to us</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>$&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->


<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="10%" ALIGN="CENTER" >
 </DIV>
<DIV style="padding:0pt;position:relative;text-align:left;margin-left:10%;">
 <DL compact>
<DT style='font-family:arial;margin-bottom:-9pt;'><FONT  style="font-size:8pt;line-height:9pt;"><font
style="font-size:6pt;position:relative;top:-2pt;add_sup:2pt;">(1)</font></FONT></DT><DD style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">We
have agreed to reimburse the underwriters for certain expenses in connection with this offering. See "Underwriting". </FONT></DD></DL>
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters also may purchase up to an additional $37,500,000 of our common stock at the public offering price, less the underwriting discounts and commissions payable by us,
within 30&nbsp;days from the date of this prospectus supplement. If the underwriters exercise this option in full, the total underwriting discounts and commissions will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and our
total proceeds, after underwriting discounts and commissions but before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are offering the common stock as set forth under "Underwriting". The underwriters expect to deliver the shares against payment therefor in New York, New York on or
about September&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:arial;"></TD>
<TD WIDTH="16%" style="font-family:arial;"></TD>
<TD WIDTH="33%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Leerink&nbsp;Partners</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2><I> Passive Book-Runner</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=4><B> Evercore ISI</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2><I> Co-Lead Manager</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=4><B> Stifel</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
Prospectus Supplement dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=396565,FOLIO='blank',FILE='DISK131:[17ZCP1.17ZCP49701]BC49701A.;21',USER='JLAWRENA',CD=';5-SEP-2017;15:23' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_bg49701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="BG49701A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> TABLE OF CONTENTS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> Prospectus Supplement  </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG49701_TOC2"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="30pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#bi49701_about_this_prospectus_supplement"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#bi49701_about_this_prospectus_supplement"><FONT SIZE=2>S-1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#bi49701_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#bi49701_forward-looking_statements"><FONT SIZE=2>S-2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ca49701_prospectus_supplement_summary"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ca49701_prospectus_supplement_summary"><FONT SIZE=2>S-4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#cc49701_the_offering"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>THE OFFERING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#cc49701_the_offering"><FONT SIZE=2>S-7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#da49701_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#da49701_risk_factors"><FONT SIZE=2>S-8</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dg49701_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dg49701_use_of_proceeds"><FONT SIZE=2>S-38</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dg49701_dilution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dg49701_dilution"><FONT SIZE=2>S-39</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dg49701_underwriting"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>UNDERWRITING</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dg49701_underwriting"><FONT SIZE=2>S-40</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A1"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>MATERIAL UNITED STATES FEDERAL INCOME AND ESTATE TAX CONSIDERATION FOR NON-U.S. HOLDERS OF SHARES OF OUR COMMON
STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A1"><FONT SIZE=2>S-46</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A2"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A2"><FONT SIZE=2>S-51</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#A3"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#A3"><FONT SIZE=2>S-51</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#di49701_incorporation_of_certain_documents_by_reference"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#di49701_incorporation_of_certain_documents_by_reference"><FONT SIZE=2>S-51</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bg49701_prospectus"> </A>
<BR></FONT><FONT SIZE=2><B>  Prospectus    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">
<A NAME="BG49701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="11pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dq49701_about_this_prospectus"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq49701_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_insmed_incorporated"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INSMED INCORPORATED</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_insmed_incorporated"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_risk_factors"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_note_regarding_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_use_of_proceeds"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_description_of_common_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_description_of_common_stock"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_plan_of_distribution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_plan_of_distribution"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_legal_matters"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_legal_matters"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_experts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_experts"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_where_you_can_find_more_information"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_where_you_can_find_more_information"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_incorporation_by_reference"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_incorporation_by_reference"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-i</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=141741,FOLIO='S-i',FILE='DISK131:[17ZCP1.17ZCP49701]BG49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_bi49701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi49701_about_this_prospectus_supplement"> </A>
<A NAME="toc_bi49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this
offering of common stock and updates the information contained in the accompanying prospectus and the documents incorporated by reference herein and therein. The second part is the accompanying
prospectus, which provides more general information, some of which does not apply to this offering. This prospectus supplement and the accompanying prospectus relate to a registration statement that
we filed with the U.S. Securities and Exchange Commission ("SEC") using a shelf registration process (File No.&nbsp;333-218118). To the extent the information contained in this prospectus supplement
differs or varies from the information contained in the accompanying prospectus or documents previously filed with the SEC that are incorporated by reference herein, the information in this prospectus
supplement will supersede such information. For a more detailed understanding of an investment in our common stock, you should read both this prospectus supplement and the accompanying prospectus,
together with the information incorporated by reference herein and therein and additional information described under the heading "Where You Can Find More Information" in the accompanying
prospectus.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You should rely only on the information contained or incorporated by reference in this prospectus and the accompanying prospectus supplement or in any related
free writing prospectus filed by us with the SEC. Neither we nor any underwriter has authorized anyone to provide you with information that is different from or in addition to such information.
Neither we nor any underwriter is making offers to sell or seeking offers to buy shares of our common stock in any jurisdiction where the offer or sale is not permitted. You should assume that the
information contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein and any related free writing prospectus is accurate only as
of the respective dates of such documents, regardless of the time of delivery of this prospectus supplement or any sale of the common stock offered hereby. Our business, financial condition, results
of operations and prospects may have changed materially since those dates.</B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Unless the context otherwise indicates, references in this prospectus supplement and the accompanying prospectus to "Insmed", the "Company", "we", "us" and "our"
refer to Insmed Incorporated, a Virginia corporation, together with its consolidated subsidiaries. INSMED and ARIKAYCE are trademarks of Insmed Incorporated. Our logos and trademarks are the property
of Insmed. All other brand names or trademarks appearing in this prospectus supplement and the accompanying prospectus are the property of their respective holders. Use or display by us of other
parties' trademarks or trade dress in this prospectus supplement and the accompanying prospectus is not intended to, and does not, imply a relationship with, or endorsements or sponsorship of, us by
the trademark or trade dress owners.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=780788,FOLIO='S-1',FILE='DISK131:[17ZCP1.17ZCP49701]BI49701A.;7',USER='VRIVERA',CD=';5-SEP-2017;02:04' -->
<A NAME="page_bi49701_1_2"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="bi49701_forward-looking_statements"> </A>
<A NAME="toc_bi49701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement, the accompanying prospectus and the other documents that are incorporated herein by reference contain
forward-looking statements that involve substantial risks and uncertainties. "Forward looking statements", as that term is defined in the Private Securities Litigation Reform Act of 1995, are
statements that are not historical facts and involve a number of risks and uncertainties. Words such as "may", "will", "should", "could", "would", "expects", "plans", "anticipates", "believes",
"estimates", "projects", "predicts", "intends", "potential", "continues", and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances)
identify forward looking statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward
looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results,
performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward
looking statements. Such risks, uncertainties and other factors include, among others, the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> risks that the full six-month data from the CONVERT study (the "CONVERT study" or the "212 study") or subsequent data from the remainder of the
study's treatment and off-treatment phases will not be consistent with the top-line six-month results of the study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the research and development of our existing product candidates, including due to delays in data readouts, such as the full
data from the CONVERT study, patient enrollment and retention or failure of our preclinical studies or clinical trials to satisfy pre-established endpoints, including secondary endpoints in the
CONVERT study and endpoints in the CONVERT extension study (the "312&nbsp;study"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain, or delays in obtaining, regulatory approval from the U.S. Food and Drug Administration ("FDA"), Japan's Ministry of Health,
Labour and Welfare ("MHLW"), the European Medicines Agency ("EMA"), and other regulatory authorities for our product candidates or their delivery devices, such as the eFlow Nebulizer System, including
due to insufficient clinical data, selection of endpoints that are not satisfactory to regulators, complexity in the review process for combination products or inadequate or delayed data from a human
factors study required for U.S. regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to maintain regulatory approval for our product candidates, if received, due to a failure to satisfy post-approval regulatory
requirements, such as the submission of sufficient data from confirmatory clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> safety and efficacy concerns related to our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lack of experience in conducting and managing preclinical development activities and clinical trials necessary for regulatory approval,
including the regulatory filing and review process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to comply with extensive post-approval regulatory requirements or imposition of significant post-approval restrictions on our product
candidates by regulators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the rate and degree of market acceptance of product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure
for distribution of our product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inaccuracies in our estimates of the size of the potential markets for our product candidates or limitations by regulators on the proposed
treatment population for our product candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=4,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=783614,FOLIO='S-2',FILE='DISK131:[17ZCP1.17ZCP49701]BI49701A.;7',USER='VRIVERA',CD=';5-SEP-2017;02:04' -->
<A NAME="page_bi49701_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure of third parties on which we are dependent to conduct our clinical trials, to manufacture sufficient quantities of our product
candidates for clinical or commercial needs, including our raw materials suppliers, or to comply with our agreements or laws and regulations that impact our business; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inaccurate estimates regarding our future capital requirements, including those necessary to fund our ongoing clinical development, regulatory
and commercialization efforts as well as milestone payments or royalties owed to third parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to develop, or to license for development, additional product candidates, including a failure to attract experienced third-party
collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the timing, scope and rate of reimbursement for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in laws and regulations applicable to our business and failure to comply with such laws and regulations; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to repay our existing indebtedness or to obtain additional capital when needed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain, protect and enforce our patents and other intellectual property and costs associated with litigation or other proceedings
related to such matters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> restrictions imposed on us by license agreements that are critical for our product development, including our license agreements with PARI
Pharma&nbsp;GmbH ("PARI") and AstraZeneca AB ("AstraZeneca"), and failure to comply with our obligations under such agreements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competitive developments affecting our product candidates and potential exclusivity related thereto; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and potential reputational damage resulting from litigation to which we are a party, including, without limitation, the class action
lawsuit pending against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of key personnel; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lack of experience operating internationally; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> risks that the net proceeds from the offering are not spent as currently intended or in ways that enhance the value of your investment in our
common stock. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not actually achieve the results, plans, intentions or expectations indicated by our forward-looking statements because, by their nature, forward-looking statements involve risks
and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These risks and uncertainties include, but are not limited to, those described in
the "Risk Factors" section of this prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. We disclaim any obligation, except as specifically
required by law, and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such
statements may be based, or that may affect the likelihood that actual results will differ from those set forth in such forward-looking statements. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein with the understanding that our actual future
results may be materially different from those expressed in forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=5,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=420225,FOLIO='S-3',FILE='DISK131:[17ZCP1.17ZCP49701]BI49701A.;7',USER='VRIVERA',CD=';5-SEP-2017;02:04' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ca49701_1_4"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ca49701_prospectus_supplement_summary"> </A>
<A NAME="toc_ca49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>This summary highlights selected information included or incorporated by reference in this prospectus supplement and
the accompanying prospectus and does not contain all of the information that may be important to you. You should carefully review this entire prospectus supplement and the accompanying prospectus,
including the risk factors and financial statements and related notes thereto included and incorporated by reference herein and therein, before making an investment decision to purchase our common
stock.</I></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Overview  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Insmed is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. Our lead product candidate is amikacin
liposome inhalation suspension ("ALIS") (formerly known as liposomal amikacin for inhalation), which is in late-stage development for adult patients with treatment refractory nontuberculous
mycobacteria ("NTM") lung disease caused by </FONT><FONT SIZE=2><I>Mycobacterium avium</I></FONT><FONT SIZE=2> complex ("MAC"), a rare and often chronic infection that can cause irreversible lung
damage and which can be fatal. Our earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase 1, an enzyme responsible for
activating neutrophil serine proteases, which are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis ("non-CF") bronchiectasis. INS1009 is an inhaled
nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension ("PAH"). </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Recent Developments  </B></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Top-Line Efficacy Data  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We recently announced top-line data for the CONVERT study, which enrolled 336 adult patients with NTM lung disease caused by MAC who were
refractory to at least six months of treatment on current guidelines-based therapy ("GBT"). After a screening period of up to 10&nbsp;weeks, eligible patients were randomized 2:1 to once-daily ALIS
plus GBT or GBT only. The primary endpoint of the study was the proportion of patients achieving culture conversion, which we defined as three consecutive monthly negative sputum cultures, by month 6.
Based on top-line results, the CONVERT study met its primary endpoint, with 29% of patients in the ALIS plus GBT arm achieving culture conversion, compared to 9% of patients in the GBT-only arm
(p&#60;0.0001). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also reported top-line data for certain secondary and exploratory endpoints for the first six months of the study. Top-line data for the six-minute walk test indicated no
statistically significant difference between patients in the two arms of the study. However, an analysis of these data (per a pre-specified exploratory endpoint) showed that patients who achieved
culture conversion in either arm demonstrated an improvement in six-minute walk distance when compared to patients who did not culture convert (p=0.0108). Top-line data for the secondary endpoint of
time to conversion demonstrated that patients in the GBT-only arm took approximately 30% longer to convert when compared to patients on ALIS plus GBT (p&#60;0.0001). We are continuing our
analysis of the impact of conversion on a variety of other clinical measures. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
plan to pursue accelerated approval of ALIS pursuant to 21 C.F.R. Part&nbsp;314 Subpart&nbsp;H (Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses)
("Subpart&nbsp;H") based on the data from the CONVERT study. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=907338,FOLIO='S-4',FILE='DISK131:[17ZCP1.17ZCP49701]CA49701A.;12',USER='JLAWRENA',CD=';5-SEP-2017;12:41' -->
<A NAME="page_ca49701_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Top-Line Safety and Tolerability Data  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approximately 98&nbsp;percent of patients in the ALIS plus GBT arm of the study experienced at least one treatment-emergent adverse event
("TEAE"), compared to 91&nbsp;percent of patients in the GBT-only arm, with most events being mild or moderate in severity. A greater percentage of patients in the ALIS plus GBT arm than in the
GBT-only arm experienced TEAEs involving dysphonia, cough, haemoptysis, dyspnoea, oropharyngeal pain, diarrhoea, nausea, and fatigue. Based on our review of the top-line study safety data, the
incidence of dysphonia, cough and dyspnoea among patients in the ALIS plus GBT arm generally decreased after the second study month. Approximately 20&nbsp;percent and 18&nbsp;percent of patients
in the ALIS plus GBT arm and GBT-only arm of the study respectively experienced at least one serious treatment emergent adverse event ("STEAE"). The table below provides additional information
regarding certain STEAEs experienced by patients in the study. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="31%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="106pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="68pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TH>
<TH ALIGN="LEFT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=5 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>2:1 Randomization </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TH NOWRAP  COLSPAN=3 ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.5pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Patients Reporting STEAEs &gt;3% in Either Arm

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>ALIS&nbsp;+&nbsp;GBT (n=223) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>GBT (n=112) </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patients Reporting At Least One STEAE</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>20.2% (45</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>17.9% (20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD NOWRAP  VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><DIV style="border-bottom:solid #000000 1.5pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2> </FONT><FONT  style="font-size:8pt;line-height:9pt;"><B>System Organ Class<BR>

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD NOWRAP  VALIGN="BOTTOM" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.5pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Preferred Term<BR>

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;"><B><BR>
&nbsp;</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:8pt;text-indent:-8pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B> </B></FONT><FONT SIZE=2>Respiratory, Thoracic, Mediastinal Disorders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>11.7% (26</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.8% (11</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Hemoptysis</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.7% (6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.5% (5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>COPD (exacerbation)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.1% (7</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.9% (1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Infections and Infestations</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>9.0% (20</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>5.4% (6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pneumonia</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>3.6% (8</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>1.8% (2</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Cardiac Disorders</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.4% (1</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.5% (5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Patient Deaths</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>2.7% (6</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>4.5% (5</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>)</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
were no distinctions between treatment arms for adverse events of hearing loss or renal impairment, side effects commonly associated with the intravenous use of amikacin. The
overall dropout rate was 16.1&nbsp;percent, with an 8.9&nbsp;percent dropout rate in the GBT-only arm and a 19.6&nbsp;percent rate in the ALIS plus GBT arm. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Market Opportunity for ALIS in NTM Lung Disease in 2018  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NTM lung disease is associated with increased rates of morbidity and mortality, and MAC is the predominant pathogenic species in NTM lung
disease in the United States, Japan and Europe. The prevalence of NTM lung disease has increased over the past two decades, and we believe it is an emerging public health concern worldwide. Based on
currently available information from external sources, including market research funded by us and third parties, and internal analyses and calculations, we estimate potential patient populations in
the United States, Japan and EU5 (comprised of France, Germany, Italy, Spain and the United Kingdom) for 2018 as follows: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:73%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"110%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="110%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="110pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="101pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="96pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH NOWRAP  ALIGN="LEFT" style="font-family:arial;"><DIV style="border-bottom:solid #000000 1.5pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Potential Market


<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

 </B></FONT></DIV></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated Number<BR>
of Patients with<BR>
Diagnosed NTM<BR>
Lung Disease </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated Number<BR>
of Patients Treated<BR>
for NTM Lung Disease Caused<BR>
by MAC </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT  style="font-size:8pt;line-height:9pt;"><B>Estimated Number<BR>
of Patients<BR>
Refractory to<BR>
Treatment </B></FONT></TH>
<TH style="font-family:arial;"><FONT  style="font-size:8pt;line-height:9pt;">&nbsp;</FONT></TH>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>United States</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>75,000&nbsp;&#150;&nbsp;105,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>40,000&nbsp;to&nbsp;50,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>10,000&nbsp;&#150;&nbsp;15,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Japan</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>125,000&nbsp;&#150;&nbsp;145,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>60,000&nbsp;&#150;&nbsp;70,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>15,000&nbsp;&#150;&nbsp;18,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EU5</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>14,000</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>4,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>1,400</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=7,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=1017637,FOLIO='S-5',FILE='DISK131:[17ZCP1.17ZCP49701]CA49701A.;12',USER='JLAWRENA',CD=';5-SEP-2017;12:41' -->
<A NAME="page_ca49701_1_6"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See
"Forward-Looking Statements" and "Risk Factors" beginning on pages&nbsp;S-2 and S-8 of this prospectus supplement for further information regarding the assumptions made in
developing these estimates and the factors that may cause them to differ materially from actual patient populations in these markets. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are not aware of any approved inhaled therapies specifically indicated for NTM lung disease in North America, Japan or Europe. Current guideline-based approaches for NTM lung
disease, including those from the American Thoracic Society and Infectious Diseases Society of America, involve multi-drug regimens not approved for the treatment of NTM lung disease and treatment
that could last two years or more. Based on a burden of illness study that we conducted in the United States with a major medical benefits provider, we previously concluded that patients with NTM lung
disease are costly to healthcare plans, while a recent claims-based study in the United States has shown that patients with NTM lung disease have higher resource utilization and costs than their age
and gender-matched controls. Accordingly, we believe that a significant market opportunity for ALIS in NTM lung disease exists in the United States and internationally. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We were incorporated in the Commonwealth of Virginia on November&nbsp;29, 1999. On December&nbsp;1, 2010, we completed a business
combination with Transave,&nbsp;Inc., a privately held New Jersey based company focused on the development of differentiated and innovative inhaled pharmaceuticals for the site specific treatment of
serious lung diseases ("Transave"). Our principal executive offices are located at 10 Finderne Avenue, Building 10, Bridgewater, NJ 08807, and our telephone number is (908)&nbsp;977-9900. Our
website address is www.insmed.com. The information on our website is not incorporated by reference into this prospectus supplement or the accompanying prospectus and should not be considered to be
part of either document. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=8,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=235178,FOLIO='S-6',FILE='DISK131:[17ZCP1.17ZCP49701]CA49701A.;12',USER='JLAWRENA',CD=';5-SEP-2017;12:41' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_cc49701_1_7"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="cc49701_the_offering"> </A>
<A NAME="toc_cc49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:100%;margin-left:0%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="32%" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="64%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock offered by us</FONT></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Common stock to be outstanding after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares
or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriter's option to purchase additional shares is exercised in full.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Use of proceeds</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We intend to use the net proceeds from this offering to fund ongoing and future clinical development of ALIS for patients
with NTM lung disease caused by MAC and our efforts to obtain potential regulatory approvals for and, if approved, commercialize ALIS in its approved indication; invest in increased third-party manufacturing capacity for and commercial inventory
production of ALIS in anticipation of possible commercial launch, initially in the United States and subsequently in Japan and other countries; fund further clinical development of INS1007; and fund working capital, potential debt repayment, capital
expenditures, general research and development; and for other general corporate purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses. See "Use of Proceeds" on page&nbsp;S-38
of this prospectus supplement for additional information.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Risk Factors</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>An investment in our common stock involves a high degree of risk. See "Risk Factors" beginning on page&nbsp;S-8 of this
prospectus supplement before deciding to invest in shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Option to purchase additional shares</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We have granted the underwriters an option for a period of 30&nbsp;days from the date of this prospectus supplement to
purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of our common stock.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Nasdaq Global Select Market listing</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Our common stock is listed on the Nasdaq Global Select Market under the symbol "INSM".</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding immediately after this offering is based on 62,376,416 shares of our common stock outstanding as of June&nbsp;30, 2017. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding immediately after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 8,621,451 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2017 at a weighted average
exercise price of $13.87 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 46,914 shares of our common stock issuable pursuant to unvested restricted stock units outstanding as of June&nbsp;30, 2017 at a weighted
average grant price of $17.16; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 4,978,554 shares of our common stock reserved for issuance under our 2017 Incentive Plan as of June&nbsp;30, 2017, plus any shares subject to
outstanding awards as of May&nbsp;18, 2017 under our 2015 Incentive Plan and 2013 Incentive Plan that subsequently are cancelled, terminated unearned, expired, forfeited, lapsed for any reason or
are settled in cash without the delivery of shares. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise stated, all information in this prospectus supplement excludes the shares referenced in the bullets immediately above and assumes no exercise by the underwriters of
their option to purchase additional shares. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=515859,FOLIO='S-7',FILE='DISK131:[17ZCP1.17ZCP49701]CC49701A.;17',USER='LBURNET',CD=';5-SEP-2017;12:38' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_da49701_1_8"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="da49701_risk_factors"> </A>
<A NAME="toc_da49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An investment in our common stock involves significant risks. Before making an investment in our common stock, you should carefully read all of
the information contained in this prospectus supplement, the accompanying prospectus and in the documents incorporated by reference herein. For a discussion of risks that you should carefully consider
before deciding to purchase any of our common stock, please review the risk factors disclosed below, together with the other information in this prospectus supplement, the accompanying prospectus, and
the information and documents incorporated by reference herein and therein. Any of these risks, as well as additional risks not currently known to us or that we currently deem immaterial, may
adversely affect our business, financial condition, results of operations, and prospects, resulting in a decline in the trading price of our common stock and loss of all or part of your investment. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Development, Regulatory Approval and Commercialization of our Product Candidates  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The currently reported results of the CONVERT study are based on top-line data for the first six months of
the study and may differ from complete study results once additional data are received and evaluated.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The reported results of our CONVERT study, which are discussed herein, consist of only top-line data from the first six months of the study.
Top-line data are based on a preliminary analysis of currently available efficacy and safety data, and therefore these currently reported results are subject to change following a comprehensive review
of the more extensive data we expect to receive for patients as of month six. Top-line data are based on important assumptions, estimations, calculations and information currently available to us, and
we have not received or had an opportunity to evaluate all of the six-month data from the CONVERT study. As a result, the top-line six-month results may differ from the full six-month data, or
different conclusions or considerations may qualify such top-line results, once the complete six-month data have been received and fully evaluated. In addition, the CONVERT study is ongoing, and
subsequent data from the treatment and off-treatment phases of the study may differ from the currently reported top-line results. If these top-line data differ from the results of the full six-month
data or subsequent data from patients during the remainder of the treatment phase or the off-treatment phase, our ability to obtain or maintain approval for, and commercialize, ALIS may be harmed,
which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our prospects are highly dependent on the success of our most advanced product candidate, ALIS. If we are
unable to successfully complete the development of, obtain or subsequently maintain regulatory approval for, and successfully commercialize ALIS, our business, financial condition, results of
operations and prospects and the value of our common stock will be materially adversely affected.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are investing significant efforts and financial resources in the development of ALIS, our most advanced product candidate. Our ability to
generate product revenue from ALIS will depend heavily on the successful completion of development of, receipt of regulatory approval for, and commercialization of, ALIS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Positive
results from preclinical studies of a product candidate may not be predictive of similar results in human clinical trials, and promising results from earlier clinical trials of
a product candidate may not be replicated in later clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials
even after achieving promising results in earlier stages of development. Accordingly, even if the full six-month </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=10,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=77539,FOLIO='S-8',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_9"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>data
for the primary endpoint are positive, such data may not be predictive of the results from the remainder of the study or the 312 study, or future trials related to ALIS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, even if we believe our clinical trials for ALIS demonstrate promising results, regulators may decline to grant regulatory approval. For instance, in the fourth quarter of
2014, we filed a marketing authorization application ("MAA") with the EMA for ALIS as a treatment for, among other things, NTM lung disease in adult patients. The filing was based in part on data from
our phase&nbsp;2 study in patients with NTM lung disease. In addition, we subsequently withdrew our MAA after the Committee for Medicinal Products for Human Use ("CHMP") concluded that the data
submitted did not provide enough evidence to support an approval. We currently expect to submit a new drug application ("NDA") to the FDA pursuant to Subpart&nbsp;H for ALIS based on the efficacy
data from the CONVERT study through month 6. Although we view the top-line six-month results from the CONVERT trial as promising, the FDA may not agree that this data is sufficient to support
submission or approval of our NDA under Subpart&nbsp;H. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Further,
even if we obtain approval for ALIS from a regulator, including from the FDA pursuant to Subpart&nbsp;H, such approval may be withdrawn under certain circumstances and
confirmatory clinical studies may be required and could fail to demonstrate sufficient safety and efficacy to support continued approval. For instance, if we obtain approval from the FDA based on the
NDA filing described above, the FDA may nonetheless conclude that the data generated from the remainder of the CONVERT study or in the 312 study is not sufficient to support continued approval of our
NDA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not expect ALIS to be commercially available in any market until we receive requisite approval from the FDA, MHLW, EMA or an equivalent regulatory agency. The failure to obtain or
subsequently maintain such approvals will materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to obtain regulatory approvals for ALIS or any other products we develop in the U.S.,
Japan, Europe or other markets. If we fail to obtain such approvals, we will not be able to commercialize our products.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are required to obtain various regulatory approvals prior to studying our products in humans and then again before we market and distribute
our products, and the failure to do so will prevent us from commercializing our products, which would materially adversely affect our business, financial condition, results of operations and prospects
and the value of our common stock. The regulatory review and approval processes in the U.S., Japan and Europe require evaluation of preclinical studies and clinical studies, as well as the evaluation
of our manufacturing process. Securing regulatory approval to market our products requires the submission of much more extensive preclinical and clinical data, manufacturing information regarding the
process and facility, scientific data characterizing our product and other supporting data to the regulatory authorities in order to establish its safety and effectiveness. These processes are
complex, lengthy, expensive, resource intensive and uncertain. We have limited experience in submitting and pursuing applications necessary to gain these regulatory approvals. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As
described above, data submitted to regulators is subject to varying interpretations that could delay, limit or prevent regulatory agency approval. We may also encounter delays or
rejections based on changes in regulatory agency policies during the period in which we develop a product and the period required for review of any application for regulatory agency approval of a
particular product. For example, the FDA has designated ALIS for fast track, breakthrough therapy and qualified infectious disease product status, all programs intended to expedite or streamline the
development and regulatory review of the drug. If we were to lose the current designation under one or more of those programs, we could face delays in the FDA review and approval process. Resolving
such delays could force us or third parties to incur significant costs, could limit our </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=11,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=944620,FOLIO='S-9',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_10"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>allowed
activities or the allowed activities of third parties, could diminish any competitive advantages that we or our third parties may attain or could adversely affect our ability to receive
royalties, any of which could materially adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. Even with these designations, there
is no guarantee we will receive approval for ALIS on a timely basis, or at all. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Similarly,
we are currently assessing our regulatory strategies with regard to orphan drug designation and other pathways that could expedite the development and regulatory review of
INS1007 in the U.S. and the EU, but we may be unsuccessful in pursuing such strategies. The FDA recently denied our initial request for orphan drug designation for INS1007 in non-CF bronchiectasis,
and we are evaluating our options, including whether to appeal this decision or
reapply for this designation based on a refined regulatory strategy. In addition, although we believe that INS1009 could be eligible for approval under Section&nbsp;505(b)(2) of the Federal Food,
Drug, and Cosmetic Act ("505(b)(2)"), and thus could rely at least in part on studies not conducted by or for us and for which we do not have a right of reference, we may not obtain approval from the
FDA to use this pathway. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Approval
by the FDA does not ensure approval by the regulatory authorities of other countries. To market our products outside of the U.S., we, and potentially our third-party providers,
must comply with numerous and varying regulatory requirements of other countries. The approval procedures vary among countries and can involve additional product testing and administrative review
periods. The time required to obtain approval in these other territories might differ from that required to obtain FDA approval. In addition, we may be subject to fines, suspension or withdrawal of
regulatory approvals, product recalls, seizure of products, operating restrictions (including with respect to our target market) and criminal prosecution if we fail to comply with applicable U.S. or
foreign regulatory requirements. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have not completed the research and development stage of ALIS or any other product candidates. If we are
unable to successfully develop and commercialize ALIS or any other products, it will materially adversely affect our business, financial condition, results of operations and prospects and the value of
our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our long-term viability and growth depend on the successful commercialization of ALIS and potentially other product candidates. Pharmaceutical
product development is an expensive, high risk, lengthy, complicated, resource intensive process. In order to conduct the development programs for our products, we must, among other things, be able to
successfully:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Identify potential product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Design and conduct appropriate laboratory, preclinical and other research; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Submit for and receive regulatory approval to perform clinical studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Design and conduct appropriate preclinical and clinical studies according to good laboratory practices and good clinical practices and
disease-specific expectations of the FDA and other regulatory bodies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Select and recruit clinical investigators and subjects for our studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Collect, analyze and correctly interpret the data from our studies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Obtain data establishing adequate safety of our product candidates and demonstrating with statistical significance that our product candidates
are effective for their proposed indications, as indicated by satisfaction of pre-established endpoints; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Submit for and receive regulatory approvals for marketing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Submit for and receive reimbursement approvals for market access; and </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=12,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=634513,FOLIO='S-10',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_11"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Manufacture the product candidates and device components according to current good manufacturing practices ("CGMP"). </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
development program with respect to any given product will take many years and thus delay our ability to generate profits associated with that product. In addition, potential
products that appear promising at early stages of development may fail for a number of reasons, including the possibility that the products may require significant additional testing or turn out to be
unsafe, ineffective, too difficult or expensive to develop or manufacture, too difficult to administer or unstable, or regulators may require additional testing to substantiate our claims. For
instance, as described above, although we view the top-line six-month results from&nbsp;the CONVERT study as promising, our clinical studies of ALIS for refractory NTM lung disease caused by MAC are
ongoing, and outcomes from those studies cannot be predicted. If we do not proceed with the development of our ALIS program in the NTM lung disease or cystic fibrosis ("CF") indications, certain of
our contract counterparties may elect to proceed with the development of these indications. Even if we are successful in obtaining regulatory approval for our product candidates, including ALIS, we
may not obtain labeling that permits us to market them with commercially viable claims because the final wording of the approved indication may be restrictive, or the available clinical data may not
provide adequate comparative data with other products. Failure to successfully commercialize our products will materially adversely affect our business, financial condition, results of operations and
prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If our clinical studies do not produce positive results or our clinical trials are delayed, or if serious
side effects are identified during drug development, we may experience delays, incur additional costs and ultimately be unable to commercialize our product candidates in the U.S., Japan, Europe or
other markets.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before obtaining regulatory approval for the sale of our product candidates, we must conduct, at our own expense, extensive preclinical tests
to demonstrate the safety of our product candidates in animals, and clinical trials to demonstrate the safety and efficacy of our product candidates in humans. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preclinical
and clinical testing is expensive, difficult to design and implement and can take many years to complete. Special challenges can arise in conducting trials in diseases or
conditions with small populations, such as difficulties enrolling adequate numbers of patients. Our product development costs have and may continue to increase if we experience further delays in
testing or approvals. A failure of one or more of our preclinical studies or clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of,
preclinical testing and the clinical trial process that could delay or prevent our ability to obtain regulatory approval or commercialize our product candidates,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our preclinical tests or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to
conduct additional preclinical testing or clinical trials or we may abandon projects that we expect to be promising; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulators, ethics committees or institutional review boards ("IRBs") may prevent us from commencing a clinical trial or conducting a clinical
trial at a prospective trial site; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Enrollment in the clinical trials may take longer than expected or the clinical trials as designed may not allow for sufficient patient accrual
to complete enrollment of the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may experience difficulties or delays due to the number of clinical sites involved in our clinical trials; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may decide to limit or abandon our commercial development programs; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=13,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=996283,FOLIO='S-11',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_12"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Conditions imposed on us by the FDA or any non-U.S. regulatory authority regarding the scope or design of our clinical trials may require us to
collect and submit information to regulatory authorities, ethics committees, IRBs or others for review and approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The number of patients required for our clinical trials may be larger than we anticipate or participants may drop out of our clinical trials at
a higher rate than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our third-party contractors, contract research organizations ("CROs"), clinical investigators, clinical laboratories, product suppliers or
nebulizer supplier may fail to comply with regulatory requirements or fail to meet their contractual obligations to us in a timely manner; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may have to suspend or terminate one or more of our clinical trials if we, regulators, ethics committees or the IRBs determine that the
participants are being exposed to unacceptable health risks or for other reasons; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may not be able to claim that a product candidate provides an advantage over current standard of care or future competitive therapies in
development because our clinical studies may not have been designed to support such claims; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulators, ethics committees or IRBs may require that we hold, suspend or terminate clinical research for various reasons, including potential
safety concerns or noncompliance with regulatory requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The cost of our clinical trials may be greater than we anticipate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The supply or quality of product used in clinical trials or other materials necessary to conduct our clinical trials may be insufficient or
inadequate or we may not be able to reach agreements on acceptable terms with prospective contract manufacturers or CROs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The effects of our product candidates may not be the desired effects or may include undesirable side effects or the product candidates may have
other unexpected characteristics; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our competitors may be able to bring products to market before we do. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete
our clinical trials or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we
may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Experience increased product development costs, as we have in the past; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Be delayed in obtaining, or be unable to obtain, regulatory approval for one or more of our product candidates; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Obtain approval for indications that are not as broad as intended or entirely different than those indications for which we sought approval or
labeling with black box or other warnings or contraindications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Have the product removed from the market after obtaining regulatory approval; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Face a shortened patent protection period during which we may have the exclusive right to commercialize our product candidates. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=14,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=459290,FOLIO='S-12',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_13"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<UL>
</UL>
</UL>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have limited experience in conducting and managing the preclinical development activities and clinical
trials necessary to obtain regulatory approvals, including approval by the FDA, MHLW, EMA and other regulatory agencies.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have limited experience in conducting and managing the preclinical development activities and clinical trials necessary to obtain regulatory
approvals, including approval by the FDA, MHLW and EMA, which might prevent us from successfully designing, implementing, or completing the clinical trials required to support regulatory approval of
our product candidates. Since our merger with Transave, we have not completed a regulatory filing and review process for, obtained regulatory approval of or commercialized any of our product
candidates. The application processes for the FDA, MHLW, Pharmaceutical and Medical Devices Agency, EMA and other regulatory agencies are complex and difficult and vary by regulatory agency, and we
have limited experience in conducting and managing the application processes necessary to obtain regulatory approvals in these various jurisdictions and might not be able to demonstrate that our
product candidates meet the appropriate standards for regulatory approval. If we are not successful in conducting and managing our preclinical development activities or clinical trials or obtaining
regulatory approvals, we might not be able to commercialize ALIS or other product candidates, or might be significantly delayed in doing so, which may materially adversely affect our business,
financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


There is little or no precedent for clinical development and regulatory expectations for agents to treat NTM
lung disease; as a result, we may encounter challenges developing clinical endpoints that will ultimately be satisfactory to regulators, which could cause our product candidates not to be approved by
regulators, delay commercialization of our product candidates or subject us to the risk of having any approval withdrawn.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on the top-line six-month data from the CONVERT study, we expect to submit an NDA under Subpart&nbsp;H to request accelerated approval
for ALIS. The FDA may base accelerated approval for drugs intended to treat serious or life-threatening illnesses that provide meaningful therapeutic benefit to patients over existing treatments on
whether the drug has an effect on a surrogate or an intermediate clinical endpoint (other than survival or irreversible morbidity). We are using a surrogate endpoint in our CONVERT study and, while we
have discussed our protocol for potential accelerated approval under Subpart&nbsp;H with the FDA, the FDA has not indicated its agreement or disagreement with the protocol. In addition, the FDA has
indicated that the results of the six-minute walk test, a secondary endpoint in the CONVERT study, will be important in assessing the results of culture conversion as a surrogate endpoint in the
CONVERT study. Developing clinical endpoints that are unsatisfactory to regulators could delay clinical trials and the FDA approval process, which could materially adversely affect our business,
financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
if ALIS or any of our other product candidates is approved based on a surrogate or an intermediate clinical endpoint under the accelerated approval regulations, the
approval will be subject to the requirement that we study the product candidate further to verify and describe its clinical benefit, where there is uncertainty as to the relation of the surrogate or
intermediate clinical endpoint to clinical benefit or of the observed clinical benefit to the ultimate outcome. Thus, even if we are successful in obtaining accelerated approval in the U.S. or under
comparable pathways in other jurisdictions, we may face requirements and limitations that will adversely affect our prospects. For example, we may be approved only for a very limited indication, we
may not successfully complete required post-approval trials, or such trials may not confirm the clinical benefit of our drug, and approval of the drug may be withdrawn. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=15,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=1043334,FOLIO='S-13',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_14"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


For ALIS to be successfully developed and commercialized in a given market, in addition to regulatory
approvals required for ALIS, the eFlow Nebulizer System must satisfy certain regulatory requirements and its use as a delivery system for ALIS must be approved or cleared by regulators.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ALIS is administered using the eFlow Nebulizer System. As such, the eFlow Nebulizer System must receive regulatory approval or clearance on its
own or in conjunction with ALIS as a combination product in order for us to develop and commercialize ALIS. Although the eFlow Nebulizer System is CE marked by PARI in the EU, outside the EU, it is
labeled as investigational for use in our clinical trials, including in the U.S., Japan, Canada and Australia. The eFlow Nebulizer System is not approved for commercial use in the U.S., Japan, Canada
or certain other markets in which we may seek to commercialize ALIS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the U.S., we plan to seek approval of the eFlow Nebulizer System in conjunction with ALIS as a combination product through a single NDA submission, and the increased complexity of
the review process in this circumstance may delay approval. Additionally, while we continue to work closely with PARI to coordinate efforts regarding regulatory requirements, we will be responsible
for this NDA submission, and we, in consultation with PARI, may not be successful in meeting the regulatory requirements for the eFlow Nebulizer System, which would prevent or delay our ability to
bring ALIS to market or to market it successfully. Further, based on our discussions to date with the FDA, we will need to conduct a human factors study for the eFlow Nebulizer System prior to
submission of our NDA for ALIS. Preparations for this study are underway, but if the study is delayed or otherwise does not yield adequate data, it could prevent or delay submission of the NDA or
approval of ALIS. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to enroll enough patients to complete our clinical trials or retain a sufficient number of
patients in our clinical trials to generate the data necessary for regulatory approval of our product candidates.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The completion rate of our clinical studies is dependent on, among other factors, the patient enrollment rate. Patient enrollment is a function
of many factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Investigator identification and recruitment; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulatory approvals to initiate study sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Patient population size; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The nature of the protocol to be used in the trial; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Patient proximity to clinical sites; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Eligibility criteria for the study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The patients' willingness to participate in the study; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Discontinuation rates; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Competition from other companies' potential clinical studies for the same patient population. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Delays
in patient enrollment for future clinical trials, such as those we encountered in enrolling the CONVERT study, could increase costs and delay ultimate commercialization and
sales, if any, of our products. Once enrolled, patients may elect to discontinue participation in a clinical trial at any time. If patients elect to discontinue participation in our clinical trials at
a higher rate than expected, we may be unable to generate the data required by regulators for approval of our product candidates. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-14</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=16,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=96663,FOLIO='S-14',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_15"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain regulatory approval for ALIS or any of our other product candidates, we will continue to
face extensive regulatory requirements and our products may face future development and regulatory difficulties.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if regulatory approval in the U.S. is obtained, the FDA may still impose significant restrictions on a product's indicated uses or
marketing, including risk evaluation and mitigation strategies ("REMS"), or may impose ongoing requirements on us, including with respect to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Labeling, such as black box or other warnings or contraindications; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Post-market surveillance, post-market studies or post-market clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of safety and other postmarket
information; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Monitoring and reporting complaints, adverse events and instances of the failure of a product to meet specifications; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Compliance with CGMPs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Changes to the approved product, product labeling or manufacturing process; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Advertising and other promotional material; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Disclosure of clinical trial results on publicly available databases. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the distribution, sale and marketing of our products are subject to a number of additional requirements, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> State wholesale drug distribution laws and the distribution of our product samples to physicians must comply with the requirements of the
Prescription Drug Marketing Act of 1987; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Sales, marketing and scientific or educational grant programs must comply with federal and state laws; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Pricing and rebate programs must comply with the Medicaid rebate requirements, and if products are made available to authorized users of the
Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
of these activities also may be subject to federal and state consumer protection and unfair competition laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we fail to comply with applicable regulatory requirements, a regulatory agency may:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Issue warning letters or untitled letters asserting that we are in violation of the law; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Seek an injunction or impose civil or criminal penalties or monetary fines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Suspend or withdraw regulatory approval; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Suspend or terminate any ongoing clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Refuse to approve pending applications or supplements to applications submitted by us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Suspend or impose restrictions on operations, including costly new manufacturing requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Refuse to allow us to enter into supply contracts, including government contracts; and/or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Impose civil monetary penalties or pursue civil or criminal prosecutions and fines against our company or responsible officers. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-15</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=17,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=790329,FOLIO='S-15',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_16"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Any
government investigation of alleged violations of law could require us to expend significant time and resources in response, and could generate negative publicity. The occurrence of any event or
penalty described above may inhibit our ability to commercialize our product candidates and generate revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The commercial success of ALIS or any other product candidates that we may develop will depend upon many
factors, including the degree of market acceptance by physicians, patients, third-party payers and others in the medical community.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even if we are able to successfully complete development of, obtain regulatory approval for, and bring to market our product candidates, they
may not gain market acceptance by physicians, patients, third-party payers and others in the medical community. If ALIS, or any other product candidate we bring to market, does not achieve an adequate
level of acceptance, we may not generate significant product revenue and we may not become profitable. The degree of market
acceptance of ALIS and any other product candidates, if approved for commercial sale, will depend on a number of factors, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The prevalence and severity of any side effects, including any limitations or warnings contained in a product's approved labeling; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The efficacy and potential advantages over alternative treatments; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The pricing of our products; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Relative convenience and ease of administration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The strength of marketing and distribution support and timing of market introduction of competitive products; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Publicity concerning our products or competing products and treatments, including competing products becoming subject to generic pricing; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Sufficient third-party insurance coverage and reimbursement. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if a potential product displays a favorable efficacy and safety profile in preclinical and clinical trials, market acceptance of the product will not be known until after it is
launched. For example, if a clinical trial is not designed to demonstrate advantages over alternative treatments, we may be prohibited from promoting our product candidates on any such advantages. Our
efforts to educate the medical community and third-party payers on the benefits of our product candidates may require significant resources and may never be successful. Such efforts to educate the
marketplace may require more resources than are required to commercialize more established technologies marketed by our competitors. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We currently have a very small marketing and sales organization, and we have limited experience as a company
in marketing drug products. If we are unable to establish our own marketing and sales capabilities, or are unable to enter into agreements with third parties, to market and sell our products after
they are approved, our ability to generate product revenues will be adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have a small commercial organization for the marketing, market access, sales and distribution of our products. In order to commercialize
ALIS or any other product candidates, we must develop these capabilities on our own or make arrangements with third parties for the marketing, sales and distribution of our products. The establishment
and development of our own sales force will be expensive and time consuming and could delay any product launch, and we may be unable to successfully develop this capability. As a result, we may seek
one or more </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-16</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=18,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=643037,FOLIO='S-16',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_17"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>partners
to handle some or all of the sales and marketing of ALIS in certain markets. However, we may not be able to enter into arrangements with third parties to sell ALIS on favorable terms or at
all. In the event we are unable to develop our own marketing, market access, and sales force or collaborate with a third-party marketing, market access, and sales organization, we may not be able to
successfully commercialize ALIS or any other product candidates that we develop, which would adversely affect our ability to generate product revenues. Further, whether we commercialize products on
our own or rely on a third party to do so, our ability to generate revenue will be dependent on the effectiveness of the sales force. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If estimates of the size of the potential markets for our product candidates, including ALIS, are overstated
or regulators limit the proposed treatment population for our product candidates, our ability to commercialize such product candidates successfully or achieve sufficient revenue to support our
business could be materially adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have relied on currently available information from external sources, including market research funded by us and third parties, and internal
analyses and calculations to estimate the potential market opportunities for NTM lung disease in 2018 in the United States, Japan and EU5. The externally sourced information used to develop these
estimates has been obtained from sources we believe to be reliable, but we have not verified the data from such sources, and their accuracy and completeness cannot be assured. Similarly, our internal
analyses and calculations are based upon management's understanding and assessment of numerous inputs and market conditions, including, but not limited to, the projected increase in prevalence of NTM
lung disease, Medicare patient population growth and ongoing population shifts to geographies with increased rates of NTM lung disease. These understandings and assessments necessarily require
assumptions subject to significant judgment and may prove to be inaccurate. As a result, our estimates of the size of these potential markets for ALIS could prove to be overstated, perhaps materially.
We may develop estimates with respect to market opportunities for other product candidates in the future, and such estimates would be subject to similar risks. In addition, a potential market
opportunity could be reduced if a regulator limits the proposed treatment population for one of our product candidates. In either circumstance, even if we obtain regulatory approval for a product
candidate, we may be unable to commercialize it on a scale sufficient to generate material revenues, which could have a material adverse effect on our business, financial condition, results of
operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Reliance on Third Parties  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We rely on third parties including collaborators, CROs, clinical and analytical laboratories, contract
manufacturing organizations ("CMOs") and other providers for many services that are critical to our business. If we are unable to form and sustain these relationships, or if any third-party
arrangements that we may enter into are unsuccessful, including due to non-compliance by such third parties with our agreements or applicable law, our ability to develop and commercialize our products
may be materially adversely affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently rely, and expect that we will in the future continue to rely, on third parties for significant research, analytical services,
preclinical development, clinical development
and manufacturing of our product candidates. For example, almost all of our clinical trial work is done by CROs, such as SynteractHCR,&nbsp;Inc., our CRO for both the 212 and 312 studies, and
clinical laboratories. Reliance on these third parties poses a number of risks, including the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Significant competition in seeking appropriate partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The complex and time-consuming nature of negotiation, documentation and implementation of agreements with third parties in the pharmaceutical
industry; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-17</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=10,SEQ=19,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=301978,FOLIO='S-17',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_18"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our potential inability to establish and implement collaborations or other alternative arrangements that we might pursue on favorable terms; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our potential inability to control whether third parties devote sufficient resources to our programs or products, including with respect to
meeting contractual deadlines; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our potential inability to control the regulatory and contractual compliance of third parties, including their processes and procedures,
systems utilized to collect and analyze data, and equipment used to test drug product and/or clinical supplies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Disagreements with third parties, including CROs, that result in a dispute over and loss of intellectual property rights, delay or termination
of research, development, or commercialization of product candidates or litigation or arbitration; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Contracts with our collaborators that fail to provide sufficient protection of our intellectual property; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Difficulty enforcing the contracts if one of these third parties fails to perform. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also rely on third parties to select and enter into agreements with clinical investigators to conduct clinical trials to support approval of our products, and the failure of these
third parties to appropriately carry out such evaluation and selection can adversely affect the quality of the data from these studies and, potentially, the approval of our products. In particular, as
part of future drug approval submissions to the FDA, we must disclose certain financial interests of investigators who participated in any of the clinical studies being submitted in support of
approval, or must certify to the absence of such financial interests. The FDA evaluates the information contained in such disclosures to determine whether disclosed interests may have an impact on the
reliability of a study. If the FDA determines that financial interests of any clinical investigator raise serious questions of data integrity, the FDA can institute a data audit, request that we
submit further data analyses, conduct additional independent studies to confirm the results of the questioned study, or refuse to use the data from the questioned study as a basis for approval. A
finding by the FDA that a financial relationship of an investigator raises serious questions of data integrity, could delay or otherwise adversely affect approval of our products. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
risks could materially harm our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not have, or may be unable to obtain, sufficient quantities of our product candidates to meet our
required supply for clinical studies or commercialization requirements, which would materially harm our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We do not have any in-house manufacturing capability other than for development and characterization and depend completely on a small number of
third-party manufacturers and suppliers for the manufacture of our product candidates on a clinical or commercial scale. For instance, we are and expect to remain dependent upon Therapure
Biopharma&nbsp;Inc. ("Therapure"), Ajinomoto Althea,&nbsp;Inc. ("Althea") and other suppliers being able to provide an adequate supply of ALIS both for our clinical trials and for commercial sale
in the event ALIS receives regulatory approvals. Althea currently manufactures ALIS at a relatively small scale. In order to meet potential commercial demand, if ALIS is approved, we have constructed
a manufacturing operation at Therapure in Canada that operates at a larger scale and intend to invest in additional production capacity for ALIS. We may not be able to secure such additional
production capacity for ALIS, which would increase the risks associated with either Therapure or Althea being unable to provide us with an adequate supply of ALIS. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also dependent upon PARI being able to provide an adequate supply of nebulizers both for our clinical trials and for commercial sale in the event ALIS receives regulatory
approval, as </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-18</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=11,SEQ=20,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=767913,FOLIO='S-18',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_19"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>PARI
is the sole manufacturer of the eFlow Nebulizer System. We have no alternative supplier for the nebulizer, and we do not intend to seek an alternative or secondary supplier. Significant effort
and time were expended in the optimization of the nebulizer for use with ALIS. In the event PARI cannot provide us with sufficient quantities of the nebulizer, replication of the optimized device by
another party may require considerable time and additional regulatory approval. In the case of certain defined supply failures, we will have the right under the our commercialization agreement with
PARI to make the nebulizer and have it made by certain third parties, but not those deemed under the commercialization agreement to compete with PARI. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
do not have long-term commercial agreements with all of our suppliers and if any of our suppliers are unable or unwilling to perform for any reason, we may not be able to locate
suppliers or enter into favorable agreements with them. In such circumstances, an inadequate supply of ALIS or the nebulizer could delay, impair or prevent clinical trials, the development and
commercialization of ALIS and adversely affect our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Financial Condition and Future Capital Requirements  </B></FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have a history of operating losses, and we currently have no material source of revenue. We expect to
incur operating losses for the foreseeable future and may never achieve or maintain profitability.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have incurred losses each previous year of our operation, except in 2009, when we sold our manufacturing facility and certain other assets
to Merck, and we did not generate material revenue during the six months ended June&nbsp;30, 2017 or the years ended December&nbsp;31, 2016, 2015 or 2014. We expect to continue incurring operating
losses for the foreseeable future. The process of developing and commercializing our products requires significant pre-clinical and clinical testing as well as regulatory approvals for
commercialization and marketing before we are allowed to begin product sales. In addition, commercialization of our product candidates would require us to significantly expand our sales and marketing
organization and establish contractual relationships to enable product manufacturing and other related activities. We expect that our activities, together with our general and administrative expenses,
will continue to result in substantial operating losses for the foreseeable future. As of June&nbsp;30, 2017, our accumulated deficit was $847.3&nbsp;million. For the six months ended
June&nbsp;30, 2017, our consolidated net loss was $82.1&nbsp;million, and we incurred a consolidated net loss of $176.3&nbsp;million for the year ended December&nbsp;31, 2016. To achieve and
maintain profitability, we need to generate significant revenues from future product sales. The process of developing and commercializing our products will require significant expenditures for
pre-clinical and clinical testing, regulatory approvals for commercialization and marketing, development of an internal or external sales and marketing organization and other related activities.
Because of the numerous risks and uncertainties associated with drug development and commercialization, we are unable to predict the extent of any future losses, and we may never generate significant
future revenues or achieve and sustain profitability. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need additional funds in the future to continue our operations, but we face uncertainties with
respect to our ability to access capital.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations have consumed substantial amounts of cash since our inception. We expect to continue to incur substantial research and
development expenses, and we expect to expend substantial financial resources to complete development of, seek regulatory approval for, and prepare for commercialization of ALIS. In addition, if we
obtain regulatory approval for ALIS or any of our other product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and
distribution. We will need
additional capital to fund these expenses. We also will require additional future capital in order to continue our other research </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-19</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=12,SEQ=21,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=339414,FOLIO='S-19',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<A NAME="page_da49701_1_20"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>and
development activities, including due to changes in our product development plans or misjudgment of expected costs, fund corporate development, maintain our intellectual property portfolio or
resolve litigation. As of June&nbsp;30, 2017, we had $91.1&nbsp;million of cash and cash equivalents on hand but no committed sources of capital. We do not know whether additional financing will
be available when needed, or, if available, that the terms will be favorable. If adequate funds are not available to us when needed, we will be forced to delay, restrict or eliminate all or a portion
of our development programs or commercialization efforts. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our loan agreement with Hercules Capital,&nbsp;Inc. ("Hercules") contains covenants and other provisions
that impose restrictions on our operations, which may adversely affect our ability to optimally operate our business or to maximize shareholder value.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our loan agreement with Hercules, under which we had outstanding indebtedness of $55.2&nbsp;million as of June&nbsp;30, 2017, contains
various restrictive covenants, including restrictions on our ability to incur additional debt, transfer or place a lien or security interest on our assets, including our intellectual property, merge
with or acquire other companies, redeem or repurchase any shares of our capital stock or pay cash dividends to our shareholders. The loan agreement also contains certain other covenants (including
limitations on other indebtedness, liens, acquisitions, investments and dividends). Upon the occurrence of an event of default, a default interest rate of an additional 5% may be applied to the
outstanding loan balances, and Hercules may terminate its lending commitment, declare all outstanding obligations immediately due and payable, and take such other actions as set forth in the loan
agreement. In addition, pursuant to the loan agreement, Hercules has the right to participate, in an amount of up to $2.0&nbsp;million, in a subsequent private financing that involves the issuance
of our equity securities. The interest-only period under the loan agreement extends through November&nbsp;1, 2018, and can be extended up to six months under certain conditions. The maturity date of
the loan facility is October&nbsp;1, 2020. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
borrowings under the loan agreement are secured by a lien on our assets, excluding our intellectual property, and in the event of a default on the loan, Hercules may have the right
to seize the assets securing our obligations under the loan agreement. The terms and restrictions provided in the loan agreement may inhibit our ability to conduct our business and to maximize
shareholder value. Future debt securities or other financing arrangements could contain negative covenants similar to, or even more restrictive than, the Hercules loan agreement. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


In-process research and development ("IPRD") comprised approximately 35% of our total assets as of
June&nbsp;30, 2017. A reduction in the value of our IPRD could have a material adverse effect on our results of operations, financial condition and the value of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As a result of the merger with Transave in 2010, we recorded an intangible IPRD asset of $77.9&nbsp;million and goodwill of
$6.3&nbsp;million on our balance sheet. As a result of the clinical hold on ALIS announced in late 2011, we recorded a charge of $26.0&nbsp;million in the fourth quarter of 2011 that reduced the
value of IPRD to $58.2&nbsp;million and reduced goodwill to zero. Potential future activities or results could result in additional writedowns of IPRD, which could materially adversely affect our
results of operations, financial condition and the value of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-20</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=13,SEQ=22,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=766620,FOLIO='S-20',FILE='DISK131:[17ZCP1.17ZCP49701]DA49701A.;15',USER='WWASSER',CD=';5-SEP-2017;12:40' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dc49701_1_21"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be unable to use our net operating losses and other tax assets.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have substantial tax loss carry forwards for U.S. federal income tax and state income tax purposes, and beginning in 2015, we had tax loss
carry forwards in Ireland as well. In general, our net operating losses and tax credits have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these
tax benefits. In particular, our ability to fully use certain U.S. tax loss carry forwards and general business tax credit carry forwards recorded prior to December 2010 to offset future income or tax
liability is limited under section&nbsp;382 of the Internal Revenue Code of 1986, as amended (the "Code"). Changes in the ownership of our stock, including those resulting from the issuance of
shares of our common stock in this or future offerings or upon exercise of outstanding options, may limit or eliminate our ability to use certain net operating losses and tax credit carry forwards in
the future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any acquisitions we make, or collaborative relationships we enter into, may require a significant amount of
our available cash and may not be clinically or commercially successful.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As part of our business strategy, we may effect acquisitions to obtain additional businesses, products, technologies, capabilities and
personnel, but we cannot assure you that we will identify suitable products or enter into such acquisitions on acceptable terms. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Acquisitions
involve a number of operational risks, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Failure to achieve expected synergies; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Difficulty and expense of assimilating the operations, technology and personnel of the acquired business; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our inability to retain the management, key personnel and other employees of the acquired business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our inability to maintain the acquired company's relationship with key third parties, such as alliance partners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Exposure to legal claims for activities of the acquired business prior to the acquisition; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The diversion of our management's attention from our core business; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The potential impairment of goodwill and write-off of IPRD costs, adversely affecting our reported results of operations and financial
condition. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also may enter into collaborative relationships that would involve our collaborators conducting proprietary development programs. Any conflict with our collaborators could limit our
ability to obtain future collaboration agreements and negatively influence our relationship with existing collaborators. Disagreements with collaborators may also develop over the rights to our
intellectual property. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we make one or more significant acquisitions or enter into a significant collaboration in which the consideration includes cash, we may be required to use a substantial portion of
our available cash and/or need to raise additional capital. For instance, in September and October of 2016, we borrowed $30.0&nbsp;million under our loan agreement with Hercules to fund the payment
due under the license agreement with AstraZeneca, and this investment&nbsp;&#151; as with any acquisition or collaboration&nbsp;&#151; may not be successful. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-21</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=23,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=507306,FOLIO='S-21',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_22"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Regulatory Matters  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The manufacturing facilities of our third-party manufacturers are subject to significant government
regulations and approvals, which are often costly and could result in adverse consequences to our business if we and our manufacturing partners fail to comply with the regulations or maintain the
approvals.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturers of our product candidates are subject to CGMP and similar standards, and while we have policies and procedures in place to select
manufacturers that adhere, and monitor their adherence to, such standards, they may nonetheless fail to do so. If one of them fails to obtain or maintain compliance or experiences problems in the
scale-up of commercial production, the production of our product candidates could be interrupted, resulting in delays, additional costs or restrictions on the marketing or sale of our products. These
manufacturers and their facilities will be subject to pre-approval CGMP inspection by the FDA and other regulatory authorities, and the findings of the CGMP inspection could result in a failure to
obtain, or a delay in obtaining, regulatory approval. In addition, these manufacturers and their facilities will be subject to continual review and periodic inspections by the FDA and other regulatory
authorities following regulatory approval, if any, of our product candidates. For instance, to monitor compliance with applicable regulations, the FDA routinely conducts inspections of facilities and
may identify potential deficiencies. The FDA issues what are referred to as "FDA Form&nbsp;483s" that set forth observations and concerns that are identified during its inspections. Failure to
satisfactorily address the concerns or potential deficiencies identified in a Form&nbsp;483 could result in the issuance of a warning letter, which is a notice of the issues that the FDA believes to
be significant regulatory violations requiring prompt corrective actions. Failure to respond adequately to a warning letter, or to otherwise fail to comply with applicable regulatory requirements
could result in enforcement, remedial and/or punitive actions by the FDA or other regulatory authorities. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Even if we obtain regulatory approval for ALIS or any of our other product candidates, adverse effects
discovered after approval could limit the commercial profile of any approved product.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If we obtain regulatory approval for ALIS or any other product candidate that we develop, such products will be used by a larger number of
patients and for longer periods of time than they were used in clinical trials. For these or other reasons, we or others may later discover that our products have adverse event profiles that limit
their usefulness or require their withdrawal. This discovery could have a number of potentially significant negative consequences, including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulatory authorities may withdraw their approval or clearance of the product and may require recall of product in distribution; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulatory authorities may require the addition of labeling statements, such as black box or other warnings or contraindications, or the
issuance of "Dear Doctor Letters" or similar communications to healthcare professionals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Regulatory authorities may impose additional restrictions on marketing and distribution of the products, or other risk management measures,
such as a REMS; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We may be required to change the way the product is administered, conduct additional clinical studies or restrict the distribution of the
product; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We could be sued and held liable for harm caused to subjects; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> We could be subject to negative publicity, including communications issued by regulatory authorities. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
of these events could prevent us from maintaining market acceptance of the affected product, cause substantial reduction in sales or substantially increase the costs of
commercializing </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-22</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=24,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=9269,FOLIO='S-22',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_23"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>our
product candidates, cause significant financial losses or result in significant reputational damage. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to obtain adequate reimbursement from governments or third-party payers for ALIS or any
other products that we may develop or if we are unable to obtain acceptable prices for those products, our prospects for generating revenue and achieving profitability may be materially adversely
affected.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our prospects for generating revenue and achieving profitability depend heavily upon the availability of adequate reimbursement for the use of
our approved product candidates from governmental and other third-party payers, both in the U.S. and in other markets. For instance, we expect a substantial majority of potential future ALIS revenues
would come from Medicare reimbursement. Reimbursement by a third-party payer may depend upon a number of factors, including the third-party payer's determination that use of a product
is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> A covered benefit under its health plan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Safe, effective and medically necessary; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Appropriate for the specific patient; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Cost-effective; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Neither experimental nor investigational. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Obtaining
reimbursement approval for a product from each government or other third-party payer is a time consuming and costly process that could require us to provide supporting
scientific, clinical and cost effectiveness data for the use of our products to each payer. We may not be able to provide data sufficient to gain acceptance with respect to reimbursement or we might
need to
conduct post-marketing studies in order to demonstrate the cost-effectiveness of any future products to such payers' satisfaction. Such studies might require us to commit a significant amount of
management time and financial and other resources. Even when a payer determines that a product is eligible for reimbursement, the payer may impose coverage limitations that preclude payment for some
uses that are approved by the FDA or non-U.S. regulatory authorities. In addition, there is a risk that full reimbursement may not be available for high priced products. Moreover, eligibility for
coverage does not imply that any product will be reimbursed in all cases or at a rate that allows us to make a profit or even cover our costs. Interim payments for new products, if applicable, also
may not be sufficient to cover our costs and may not be made permanent. Subsequent approvals of competitive products could result in a detrimental change to the reimbursement of our products. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
is a significant focus in the U.S. healthcare industry and elsewhere on cost containment and value. We expect changes in the Medicare program and state Medicaid programs, as well
as managed care organizations and other third-party payers, to continue to put pressure on pharmaceutical product pricing. For instance, the Medicare Prescription Drug, Improvement, and Modernization
Act of 2003 ("MMA") expanded Medicare outpatient prescription drug coverage for the elderly through Part&nbsp;D prescription drug plans sponsored by private entities and authorized such plans to use
formularies where they can limit the number of drugs that will be covered in any therapeutic class. The plans generally negotiate significant price concessions as a condition of formulary placement.
The MMA also introduced a new reimbursement methodology based on average sales prices for physician-administered drugs, which is generally believed to have resulted in lower Medicare reimbursement for
physician-administered drugs. These cost reduction initiatives and other provisions of this legislation provide additional pressure to contain and reduce drug prices and could decrease the coverage
and price that we receive for any approved products and could seriously harm our business. Although the MMA applies only to drug benefits for Medicare </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-23</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=25,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=887854,FOLIO='S-23',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_24"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>beneficiaries,
private payers often follow Medicare coverage policy and payment limitations when setting their own reimbursement rates, and any reimbursement reduction resulting from the MMA may
result in a similar reduction in payments from private payers. Additionally, the Patient Protection and Affordable Care Act ("ACA") revised the definition of "average manufacturer price" for reporting
purposes, which could increase the amount of Medicaid drug rebates to states, and has imposed a significant annual fee on companies that manufacture or import branded prescription drug products. We
believe it is likely that the ACA, or any legislation enacted to replace it, will continue the pressure on pharmaceutical pricing, especially under the Medicare program, and also may increase our
regulatory burdens and operating costs. If one or more of our product candidates reaches commercialization, such changes may have a significant impact on our ability to set a price we believe is fair
for our products and may adversely affect our ability to generate revenue and achieve or maintain profitability. We expect further federal and state proposals and health care reforms to continue to be
proposed by legislators and/or the U.S. President, which could limit the prices that can be charged for the products we develop and may limit our commercial opportunity. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Moreover,
in markets outside the U.S., including Japan, Canada and the countries in the EU, pricing of pharmaceutical products is subject to governmental control. Evaluation criteria
used by many EU government agencies for the purposes of pricing and reimbursement typically focus on a product's degree of innovation and its ability to meet a clinical need unfulfilled by currently
available therapies. The ACA created a similar entity, the Patient-Centered Outcomes Research Institute ("PCORI") designed to review the effectiveness of treatments and medications in federally-funded
health care programs. The PCORI began its first research initiatives recently, and an adverse result may result in a treatment or product being removed from Medicare or Medicare coverage. The
decisions of such governmental agencies could affect our ability to sell our products profitably. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Government health care reform could increase our costs, and could materially adversely affect our business,
financial condition, results of operations and prospects and the value of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our industry is highly regulated and changes in or revisions to laws and regulations that make gaining regulatory approval, reimbursement and
pricing more difficult or subject to different criteria and standards may adversely impact our business, operations or financial results. For example, under the ACA, drug manufacturers are required to
report information on payments or transfers of value to U.S. physicians and teaching hospitals as well as investment interests held by physicians and their immediate family members. Failure to submit
required information may result in civil monetary penalties. The reported data is posted in searchable form on a public website. In addition, some states, as well as other countries, including France,
require the disclosure of certain payments to health care professionals. In the coming years, we expect additional and potentially substantial, changes to governmental programs that could
significantly impact the success of our product candidates. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Administration and the majority party in both Houses of Congress have indicated their ongoing desire to repeal the ACA. It is unclear whether, when and how that repeal may be
effectuated and what the effect on the healthcare sector will be. The U.S. President has indicated an interest in having the federal government negotiate drug prices with pharmaceutical manufacturers.
Changes to the ACA, to the Medicare or Medicaid programs, or to the ability of the federal government to negotiate drug prices, or other federal legislation regarding healthcare access, financing or
legislation in individual states, could affect our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-24</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=26,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=296591,FOLIO='S-24',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_25"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We will need approval from the FDA and other regulatory authorities in jurisdictions outside the U.S. for our
proposed trade names. Any failure or delay associated with such approvals may delay the commercialization of our products.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any trade name we intend to use for our product candidates will require approval from the FDA regardless of whether we have secured a formal
trademark registration from the U.S. Patent and Trademark Office ("PTO"). The FDA typically conducts a rigorous review of proposed trade names, including an evaluation of potential for confusion with
other trade names and medication error. The FDA also may object to a trade name if it believes the name is inappropriately promotional. Even after the FDA approves a trade name, the FDA may request
that we adopt an alternative name for the product if adverse event reports indicate a potential for confusion with other trade names and medication error. If we are required to adopt an alternative
name, the commercialization of ALIS could be delayed or interrupted, which would limit our ability to commercialize ALIS and generate revenues. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are found in violation of federal or state "fraud and abuse" laws, we may be required to pay a penalty
or may be suspended from participation in federal or state health care programs, which may adversely affect our business, financial condition, results of operations and prospects and the value of our
common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the U.S., we are subject to various federal and state health care "fraud and abuse" laws, including anti-kickback laws, false claims laws
and other laws intended to reduce fraud and abuse in federal and state health care programs. Although we seek to structure our business arrangements in compliance with all applicable requirements,
these laws are broadly written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it is possible that our practices may be challenged
under these laws. Violations of fraud and abuse laws may be punishable by criminal and/or civil sanctions, including fines or exclusion or suspension from federal and state health care programs such
as Medicare and Medicaid and debarment from contracting with the U.S. government, and our business, financial condition, results of operations and prospects and the value of our common stock may be
adversely affected. Our reputation could also suffer. In addition, private individuals have the ability to bring actions on behalf of the government under the federal False Claims Act as well as under
the false claims laws of several states. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Several
states also impose other marketing restrictions or require pharmaceutical companies to make marketing or price disclosures to the state. Health record privacy laws may limit
access to information identifying those individuals who may be prospective users or prohibit contact with any persons enrolled in Medicare or Medicaid. There are ambiguities as to what is required to
comply with these state requirements, and we could be subject to penalties if a state determines that we have failed to comply with an applicable state law requirement. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Intellectual Property  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are unable to protect our intellectual property rights adequately, the value of our product candidates
could be diminished.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal, technical,
scientific and factual questions, and our success depends in large part on our ability to protect our proprietary technology and to obtain patent protection for our products, prevent third parties
from infringing on our patents, both domestically and internationally. We have sought to protect our proprietary position by filing patent applications in the U.S. and abroad related to our novel
technologies and products that are important to our business. This process is expensive and time-consuming, and we may not be able to file and </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-25</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=27,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=891012,FOLIO='S-25',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_26"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>prosecute
all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and
development output before it is too late to obtain patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from using our technologies
or from developing competing products and technologies. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Even
if our owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing
with us or otherwise provide us with any competitive advantage. Any conclusions we may reach regarding non-infringement, inapplicability or invalidity of a third party's intellectual property
vis-&agrave;-vis our proprietary rights, or those of a licensor, are based in significant part on a review of publicly available databases and other information. There may be information not
available to us or otherwise not reviewed by us that could render these conclusions inaccurate. Our competitors may also be able to circumvent our owned or licensed patents by developing similar or
alternative technologies or products in a non-infringing manner. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
patents issued to us or our licensors may be challenged, narrowed, invalidated, held to be unenforceable or circumvented through litigation, which could limit our ability
to stop competitors from marketing similar products or reduce the term of patent protection we may have for our products. U.S. patents and patent applications may also be subject to interference or
derivation proceedings, and U.S. patents may be subject to re-examination proceedings, reissue, post-grant review and/or </FONT><FONT SIZE=2><I>inter partes</I></FONT><FONT SIZE=2> review in the PTO.
Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office, which could result in either loss of the patent or denial of the patent application
or loss or reduction in the scope of one or more of the claims of the patent or patent application. See </FONT><FONT SIZE=2><I>Intellectual Property&nbsp;&#151; ARIKAYCE Patents and Trade
Secrets</I></FONT><FONT SIZE=2> in Item&nbsp;1 of Part&nbsp;I of our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016 (the "2016 Annual Report") for information on our
European patent that was previously opposed, the decision of which is now under appeal by Generics (UK)&nbsp;Ltd, and our European patent that is currently being opposed by Generics (UK)&nbsp;Ltd. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Changes
in either patent laws or in interpretations of patent laws in the U.S. and other countries may also diminish the value of our intellectual property or narrow the scope of our
patent protection, including making it easier for competitors to challenge our patents. For example, the America Invents Act included a number of changes to established practices, including the
transition to a first-inventor-to-file system and new procedures for challenging patents and implementation of different methods for invalidating patents. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we are not able to adequately prevent disclosure of trade secrets and other proprietary information, the
value of our product candidates could be significantly diminished.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We rely on trade secrets to protect our proprietary technologies, especially where we do not believe patent protection is appropriate or
obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, advisors, collaborators, and other third parties and
partners to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information or may not provide an adequate remedy in
the event of unauthorized disclosure of confidential information. In addition, third parties may independently develop or discover our trade secrets and proprietary information. Regulators also may
disclose information we consider to be proprietary to third parties under certain circumstances, including in response to third-party requests for such disclosure under the Freedom of Information Act
or comparable laws. Additionally, the FDA, as part of its Transparency Initiative continues to consider whether to make additional information publicly available on a routine basis, including
information that we may consider to be trade secrets or other </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-26</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=28,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=476047,FOLIO='S-26',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_27"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>proprietary
information, and it is not clear at the present time whether and how the FDA's disclosure policies may change in the future. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may not be able to enforce our intellectual property rights throughout the world.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have
encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do
not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents
or in-licensed patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner may be required
to grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries,
patents may provide limited or no benefit. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Proceedings
to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Our efforts
to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability
to obtain adequate protection for our technology and to enforce intellectual property rights. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may infringe the intellectual property rights of others, which may prevent or delay our product
development efforts, prevent us from commercializing our products or increase the costs of commercializing our products.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Third parties may claim that we have infringed upon or misappropriated their proprietary rights. Any existing third-party patents, or patents
that may later issue to third parties, could negatively affect our commercialization of ALIS, INS1007, INS1009 or any other product. For instance, PAH is a competitive indication with established
products, including other formulations of treprostinil. Our supply of the active pharmaceutical ingredient for INS1009 is dependent upon a single supplier. The supplier owns patents on its
manufacturing process, and we have filed patent applications for INS1009; however, a competitor in the PAH indication may claim that we or our supplier have infringed upon or misappropriated its
proprietary rights. Moreover, in the event that
we pursue approval of INS1009, or any other product candidate, via the 505(b)(2) regulatory pathway, we will be required to file&nbsp;a certification against any unexpired patents listed in the
Orange Book for the third party drug we rely upon as part of our regulatory submission. This certification process may lead to litigation and could delay also launch of a product candidate. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event of a successful claim against us for infringement or misappropriation of a third party's proprietary rights, we may be required to take actions including but not limited to
the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Pay damages, including up to treble damages, royalties, and the other party's attorneys' fees, which may be substantial; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Cease the development, manufacture, marketing and sale of products or use of processes that infringe the proprietary rights of others; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Expend significant resources to redesign our products or our processes so that they do not infringe the proprietary rights of others, which may
not be possible; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Redesign our products or processes to avoid third-party proprietary rights, which means we may suffer significant regulatory delays associated
with conducting additional clinical trials or other steps to obtain regulatory approval; and/or </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-27</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=29,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=1004088,FOLIO='S-27',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_28"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Obtain one or more licenses arising out of a settlement of litigation or otherwise from third parties which license(s) may not be available to
us on acceptable terms or at all. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Such
litigation, and any resulting resolution, could have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common
stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Any lawsuits or other proceedings relating to infringement or enforcement by us or third parties of
intellectual property rights or challenges to the scope and validity of such rights may be costly and time consuming.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may have to undertake costly litigation or engage in other proceedings, such as interference or inter partes review, to enforce any patents
issued or licensed to us, to confirm the scope and validity of our or a licensor's proprietary rights or to defend against allegations that we have infringed a third party's intellectual property
rights. Such proceedings are likely to be time consuming and may divert management attention from operation of our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain of our existing license agreements include, and our future license agreements also may include,
restrictions on our ability to freely develop or commercialize the product candidates that are subject to those agreements. If we fail to comply with our obligations under these agreements, or if
these license agreements are terminated for other reasons, we could lose license rights that are important to our business.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a party to licensing agreements with PARI and AstraZeneca, which we view as material to our business. For additional information
regarding the terms of these agreements, see </FONT><FONT SIZE=2><I>Business&nbsp;&#151; License and Other Agreements</I></FONT><FONT SIZE=2> in Item&nbsp;1 of Part&nbsp;I of our 2016
Annual Report. Under our license agreement with AstraZeneca, AstraZeneca retains a right of first negotiation pursuant to which it may exclusively negotiate with us before we can negotiate with a
third party regarding any transaction to develop or commercialize INS1007, subject to certain exceptions. While this right of first negotiation is not triggered by a change of control, it may impede
or delay our ability to consummate certain other transactions involving INS1007. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additionally,
if we fail to comply with our obligations under the agreements with PARI and AstraZeneca, our counterparty may have the right to take action against us, up to and
including termination of the relevant license. For instance, under our licensing agreement with PARI, with respect to NTM, CF and bronchiectasis, we have specific obligations to use commercially
reasonable efforts to achieve certain developmental and regulatory milestones by set deadlines.
Additionally, for NTM, we are obligated to use commercially reasonable efforts to achieve certain commercial milestones in the U.S. and Europe. The consequences of our failing to use commercially
reasonable efforts to achieve certain commercial milestones are context-specific, but include ending PARI's non-compete obligation, making the license non-exclusive and terminating the license, in
each case with respect to the applicable indication. Similarly, under our license agreement with AstraZeneca, AstraZeneca may terminate our license to INS1007 if we fail to use commercially reasonable
efforts to develop and commercialize a product based on INS1007, or we are subject to a bankruptcy or insolvency. Reduction or elimination of our licensed rights may result in our having to negotiate
new or reinstated licenses with less favorable terms and may materially harm our business. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-28</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=30,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=84712,FOLIO='S-28',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_dc49701_1_29"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Industry  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We operate in a highly competitive and changing environment, and if we are unable to adapt to our
environment, we may be unable to compete successfully.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biotechnology and related pharmaceutical technology have undergone and are likely to continue to experience rapid and significant change. We
expect that the technologies associated with biotechnology research and development will continue to develop rapidly. Our future success will depend in large part on our ability to maintain a
competitive position with respect to these technologies and to obtain and maintain protection for our intellectual property. Any compounds, products or processes that we develop may become obsolete
before we recover any expenses incurred in connection with their development. In each of our potential product areas, we face substantial competition from pharmaceutical, biotechnology and other
companies, universities and research institutions. Relative to us, most of these entities have substantially greater capital resources, research and development staffs, facilities and experience in
conducting clinical studies and obtaining regulatory approvals, as well as in manufacturing and marketing pharmaceutical products. Many of our competitors may achieve product commercialization or
obtain patent protection earlier than us. Furthermore, we believe that our competitors have used, and may continue to use, litigation to gain a competitive advantage. Our competitors may also use
different technologies or approaches to the development of products similar to the products we are seeking to develop. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
expect that competing successfully will depend, among other things, on product efficacy, safety, reliability, availability, timing and scope of regulatory approval and price.
Specifically, we expect crucial factors will include the relative speed with which we can develop products, complete the clinical testing and regulatory approval processes and supply commercial
quantities of the product to the market. We expect competition to increase as technological advances are made and commercial applications broaden. There are potential competitive products, both
approved and in development, which include oral, systemic, or inhaled antibiotic products to treat chronic respiratory infections. For instance, certain entities have expressed interest in studying
their products for NTM lung disease and are seeking to advance studies in NTM lung disease caused by mycobacterial species other than MAC; however, we are not aware that any such entities are
currently conducting clinical trials for the treatment of refractory NTM lung disease caused by MAC or of any approved inhaled therapies specifically indicated for NTM lung disease in North America,
Japan or Europe. If any of our competitors develops a product that is more effective, safe, tolerable or, convenient or less expensive than ALIS or our other product candidates, it would likely
materially adversely affect our ability to generate revenues. We also may face lower priced generic competitors if third-party payers encourage use of generic or lower-priced versions of our product
or if competing products are imported into the U.S. or other countries where we may sell ALIS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, there are other amikacin products that have been approved by the FDA, MHLW and other regulatory agencies for use in other indications, and physicians may elect to prescribe
those products rather than ALIS to treat the indications for which ALIS may receive approval, which is commonly referred to as off-label use. Although regulations prohibit a drug company from
promoting off-label use of its product, the FDA and other regulatory agencies do not regulate the practice of medicine and cannot direct physicians as to what product to prescribe to their patients.
As a result, we would have limited ability to prevent any off-label use of a competitor's product to treat diseases for which we have received FDA or other regulatory agency approval, even if such use
violates our patents or orphan drug exclusivity for the use of amikacin to treat such diseases. If we are unable to compete successfully, it will materially adversely affect our business, financial
condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-29</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=9,SEQ=31,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=525150,FOLIO='S-29',FILE='DISK131:[17ZCP1.17ZCP49701]DC49701A.;9',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_de49701_1_30"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If another party obtains orphan drug exclusivity for a product that is essentially the same as a product we
are developing for a particular indication, we may be precluded or delayed from commercializing the product in that indication.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under the Orphan Drug Act, the FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition. The company that
obtains the first regulatory approval from the FDA for a designated orphan drug for a rare disease receives marketing exclusivity for use of that drug for the designated condition for a period of
seven years. Similar laws exist in the EU with a term of ten years. See </FONT><FONT SIZE=2><I>Business&nbsp;&#151; Government Regulation&nbsp;&#151; Orphan
Drugs</I></FONT><FONT SIZE=2> in Item&nbsp;1 of Part&nbsp;I of our 2016 Annual Report for additional information. If a competitor obtains approval of the same drug for the same indication or
disease before us, we would be prohibited from obtaining approval for our product for seven or more years, unless our product can be shown to be clinically superior. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If we obtain orphan exclusivity for a product, the FDA may approve another product during our orphan
exclusivity period for the same indication under certain circumstances.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Orphan Drug Act was created to encourage companies to develop therapies for rare diseases by providing incentives for drug development and
commercialization. One of the incentives provided by the act is seven years of market exclusivity in the U.S. for the first product in a class licensed for the treatment of a rare disease. Orphan
exclusivity does not, however, bar approval of another product under certain circumstances. One such circumstance is if a product with the same active ingredient is proven safe and effective for a
different indication. Another circumstance is if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of
greater efficacy or safety, or providing a major contribution to patient care. The FDA may also approve another product with the same active ingredient and the same indication if the company with
orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease as long as the products contain different active
ingredients. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same
indication or disease. All of the above circumstances could create a more competitive market for us and could have a material adverse effect on our business. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our research, development and manufacturing activities used in the production of ALIS involve the use of
hazardous materials, which could expose us to damages, fines, penalties and sanctions and materially adversely affect our results of operations and financial condition.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the
handling, use, storage, treatment and disposal of hazardous materials and wastes. Our research and development program and manufacturing activities for ALIS and our other product candidates involve
the controlled use of hazardous materials and chemicals. We generally contract with third parties for the disposal of these materials and wastes. Although we strive to comply with all pertinent
regulations, we cannot eliminate the risk of environmental contamination, damage to facilities or injury to personnel from the accidental or improper use or control of these materials. In addition to
any liability we could have for any misuse by us of hazardous materials and chemicals, we could also potentially be liable for activities of our CMOs or other third parties. Any such liability, or
even allegations of such liability, could materially adversely affect our results of operations and financial condition. We also could incur significant costs associated with civil or criminal fines
and penalties. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-30</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=674618,FOLIO='S-30',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_31"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>may
impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We may be subject to product liability claims, and we have only limited product liability insurance.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The manufacture and sale of human therapeutic products involve an inherent risk of product liability claims, which can lead to significant
adverse publicity and obligations to pay damages. We currently have only limited product liability insurance for our products. We do not know if we will be able to maintain existing, or obtain
additional, product liability insurance on acceptable terms or with adequate coverage against potential liabilities. This type of insurance is expensive and may not be available on acceptable terms.
If we are unable to obtain or maintain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to commercialize our
products. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts and may materially adversely affect our
business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Employee Matters and Managing Growth  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are dependent upon retaining and attracting key personnel, the loss of whose services could materially
adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We depend heavily on our management team and our principal clinical and commercial personnel, the loss of whose services might significantly
delay or prevent the achievement of our research, development or business objectives. Our success depends, in large part, on our ability to attract and retain qualified management, clinical and
commercial personnel, and on our ability to develop and maintain important relationships with commercial partners,
leading research institutions and key distributors. We plan to hire additional personnel in anticipation of seeking regulatory approval for and commercial launch of ALIS. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Competition
for skilled personnel in our industry and market is very intense because of the numerous pharmaceutical and biotechnology companies that seek similar personnel. These
companies may have greater financial and other resources, offer a greater opportunity for career advancement and have a longer history in the industry than we do. We also experience competition for
the hiring of our clinical and commercial personnel from universities, research institutions, and other third parties. We cannot assure that we will attract and retain such persons or maintain such
relationships. Our inability to retain and attract qualified employees would materially harm our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We expect to expand our development, manufacturing, regulatory and future sales and marketing capabilities,
and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We expect that our potential expansion into areas and activities requiring additional expertise, such as further clinical trials, governmental
approvals, manufacturing, sales, marketing and distribution will place additional requirements on our management, operational and financial resources. Future growth would impose significant added
responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate
amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-31</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=33,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=879307,FOLIO='S-31',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_32"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>growth
activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business
opportunities, loss of employees and reduced productivity among remaining employees. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
anticipated commercialization of ALIS and the development of additional product candidates will require significant expenditures by us and place a strain on our resources. If our
management is unable to effectively manage our activities in anticipation of commercialization, as well as our development efforts, we may incur higher than expected expenditures or other expenses and
our business may otherwise be adversely affected. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to Our Common Stock and Listing on the Nasdaq Global Select Market  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


The market price of our stock has been and may continue to be highly volatile.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Select Market under the ticker symbol "INSM". The market price of our stock has been and may
continue to be highly volatile, and could be subject to wide fluctuations in price in response to various factors, including those discussed herein, many of which are beyond our control. In addition,
the stock market has from time to time experienced extreme price and volume fluctuations, which have particularly affected the market prices for emerging biotechnology and pharmaceutical companies
like us, and which have often been unrelated to their operating performance. These broad market fluctuations may adversely affect the market price of our common stock. Historically, when the market
price of a stock has been volatile, shareholders are more likely to institute securities and derivative class action litigation against the issuer of such stock. As described below, a securities class
action lawsuit was initiated against us during 2016 following a decline in our stock price. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We, certain of our executive officers and directors and the underwriters from a prior securities offering are
subject to a securities class action lawsuit, which may require significant management and board time and attention and significant expense to us and result in an unfavorable outcome, which could have
a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We, certain of our executive officers and directors and the underwriters from a prior securities offering have been named as defendants in a
securities class action lawsuit initially filed on July&nbsp;15, 2016. The amended complaint, filed December&nbsp;15, 2016, alleges that we and certain of our executive officers and directors
violated Sections&nbsp;11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"), and that we, certain of our executive officers and the underwriters violated
Section&nbsp;10(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and Rule&nbsp;10b-5 promulgated thereunder of the Exchange Act, by making materially false and misleading
statements and omissions relating to the development of ALIS and/or related requests for regulatory approval. It also alleges that the defendant officers and directors violated Section&nbsp;15 of
the Securities Act and that the defendant officers violated Section&nbsp;20(a) of the Exchange Act. For additional information, see Note&nbsp;9, Commitments and Contingencies, in Item&nbsp;1 of
Part&nbsp;1 of our Quarterly Report on Form&nbsp;10-Q for the quarter ended June&nbsp;30, 2017. While we believe that we have substantial legal and factual defenses to the claims in the class
action and intend to
vigorously defend the case, this lawsuit could divert our management's and board's attention from other business matters, the outcome of the pending litigation is difficult to predict and quantify,
and the defense against the underlying claims will likely be costly. The ultimate resolution of this matter could result in payments of monetary damages or other costs, materially and adversely affect
our business, financial condition and results of operations, and adversely affect our reputation and prospects, and consequently, could negatively impact the value of our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-32</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=34,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=101407,FOLIO='S-32',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_33"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have insurance policies related to the risks associated with our business, including directors' and officers' liability insurance policies. However, there is no assurance that our
insurance coverage will be sufficient or that our insurance carriers will cover all claims in that litigation. If we are not successful in our defense of the claims asserted in the putative action and
those claims are not covered by insurance or exceed our insurance coverage, we may have to pay damage awards, indemnify our executive officers and directors from damage awards that may be entered
against them and pay the costs and expenses incurred in defense of, or in any settlement of, such claims. In addition, we are indemnifying the underwriters that are party to this action against the
claims asserted against them, and these costs and expenses might not be covered by insurance. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, there is the potential for additional shareholder litigation against us, and we could be materially and adversely affected by such matters. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and
arrangements between us and our employees could hamper a third party's acquisition of, or discourage a third party from attempting to acquire control of us.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions of Virginia law, our articles of incorporation and amended and restated bylaws and arrangements with our employees could
hamper a third party's acquisition of, or discourage a third party from attempting to acquire control of, us or limit the price that investors might be willing to pay for shares of our common stock.
These provisions or arrangements include:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The ability to issue preferred stock with rights senior to those of our common stock without any further vote or action by the holders of our
common stock. The issuance of preferred stock could decrease the amount of earnings and assets available for distribution to the holders of our common stock or could adversely affect the rights and
powers, including voting rights, of the holders of our common stock. In certain circumstances, such issuance could have the effect of decreasing the market price of our common stock. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The existence of a staggered board of directors in which there are three classes of directors serving staggered three-year terms, thus
expanding the time required to change the composition of a majority of directors. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The requirement that shareholders provide advance notice when nominating director candidates to serve on our Board of Directors. </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The inability of shareholders to convene a shareholders' meeting without the chairman of the board, the president or a majority of the board of
directors first calling the meeting. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> The prohibition against entering into a business combination with the beneficial owner of 10% or more of our outstanding voting stock for a
period of three years after the 10% or greater owner first reached that level of stock ownership, unless certain criteria are met. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> In addition to severance agreements with our officers and provisions in our incentive plans that permit acceleration of equity awards upon a
change in control, a severance plan for eligible full-time employees that provides such employees with severance equal to six months of their then-current base salaries in connection with a
termination of employment without cause upon, or within 18&nbsp;months following, a change in control. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
previously had a shareholder rights plan, or "poison pill", which expired in May 2011. Under Virginia law, our Board of Directors may implement a new shareholders' rights plan
without shareholder approval. Our Board of Directors intends to regularly consider this matter, even in the absence of specific circumstances or takeover proposals, to facilitate its future ability to
quickly and effectively protect shareholder value. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-33</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=35,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=485093,FOLIO='S-33',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_34"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Risks Related to Our Business  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We have limited experience operating internationally, are subject to a number of risks associated with our
international activities and operations and may not be successful in our efforts to expand internationally.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We currently have limited operations outside of the U.S. As of June&nbsp;30, 2017, we had 24 employees located in Europe, and we have
suppliers located around the world. In order to meet our long-term goals, we will need to grow our international operations over the next several years, including in Japan, and continue to source
material used in the manufacture of our product candidates from abroad. Consequently, we are and will continue to be subject to additional risks related to operating in foreign countries,
including:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Our limited experience operating our business internationally; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> An inability to achieve the optimal pricing and reimbursement for ALIS or subsequent changes in reimbursement, pricing and other regulatory
requirements; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Any implementation of, or changes to, tariffs, trade barriers and other import-export regulations in the U.S. or other countries in which we
operate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Unexpected adverse events related to ALIS or our other product candidates occurring in foreign markets that we have not experienced in the
U.S.; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Economic and political conditions, including geopolitical events, such as war and terrorism, foreign currency fluctuations and inflation, which
could result in increased or unpredictable operating expenses and reduced revenues and other obligations incident to doing business in, or with a company located in, another country; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Changes resulting from (i)&nbsp;the uncertainty and instability in economic and market conditions caused by the UK's vote to exit the
European Union; and (ii)&nbsp;the uncertainty regarding how the UK's access to the EU Single Market and the wider trading, legal, regulatory and labor environments will be impacted by the UK's vote
to exit the European Union, including the resulting impact on our business; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Compliance with foreign or U.S. laws, rules and regulations, including data privacy requirements, labor relations laws, tax laws,
anticompetition regulations, import, export and trade restrictions, anti- bribery/anti-corruption laws, regulations or rules, which could lead to actions by us or our licensees, distributors,
manufacturers, other third parties who act on our behalf or with whom we do business in foreign countries or our employees who are working abroad that could subject us to investigation or prosecution
under such foreign or U.S. laws. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>These
and other risks associated with our international operations may materially adversely affect our business, financial condition, results of operations and prospects and the value of our common
stock. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer
security breaches, which could result in a material disruption of our business operations, including our drug development programs.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions
in our operations, it could result in a material adverse effect on our business operations, including a material disruption of our drug </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-34</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=36,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=986983,FOLIO='S-34',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_35"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>development
programs. Unauthorized disclosure of sensitive or confidential client or employee data, whether through breach of computer systems, systems failure, employee negligence, fraud or
misappropriation, or otherwise, could damage our reputation. Similarly, unauthorized access to or through our information systems and networks, whether by our employees or third parties, could result
in negative publicity, legal liability and damage to our reputation. For example, the loss of clinical trial data from completed or ongoing clinical trials for any of our product candidates could
result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss
of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could
be delayed. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Although
we have general liability insurance coverage, including coverage for errors or omissions, our insurance may not cover all claims, continue to be available on reasonable terms
or be sufficient in amount to cover one or more large claims; additionally, the insurer may disclaim coverage as to any future claim. The successful assertion of one or more large claims against us
that exceed or are not covered by our insurance coverage or changes in our insurance policies, including premium increases or the imposition of large deductible or co-insurance requirements, could
have a material adverse effect on our business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>


<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


We are subject to the U.S. Foreign Corrupt Practices Act, the UK Bribery Act and other anti-corruption laws
and trade control laws, as well as other laws governing our operations. If we fail to comply with these laws, we could be subject to negative publicity, civil or criminal penalties, other remedial
measures, and legal expenses, which could adversely affect our business, financial condition, results of operations and prospects and the value of our common stock.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act ("FCPA"), the UK Bribery Act and other
anticorruption laws that apply in countries where we do business. The FCPA, UK Bribery Act and these other laws generally prohibit us, our employees and our intermediaries from making prohibited
payments to government officials or other persons to obtain or retain business or gain some other business advantage. We have conducted the CONVERT study at more than 125 sites in 18 countries, and we
are conducting the 312 study and plan to conduct the WILLOW study, our global phase&nbsp;2 study of INS1007 in non-CF bronchiectasis, at a broad range of trial sites around the world. Certain of
these jurisdictions pose a risk of potential FCPA violations, and we have relationships with third parties whose actions could potentially subject us to liability under the FCPA or local
anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which
existing laws might be administered or interpreted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are also subject to other laws and regulations governing our international operations, including regulations administered by the U.S. Department of Commerce's Bureau of Industry and
Security, the U.S. Department of Treasury's Office of Foreign Assets Control, and various non-U.S. government entities, including applicable export control regulations, economic sanctions on countries
and persons, customs requirements, currency exchange regulations and transfer pricing regulations (collectively, "Trade Control laws"). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may not be effective in ensuring our compliance with all applicable anticorruption laws, including the FCPA or other legal requirements, including Trade Control laws. If we are not
in compliance with the FCPA and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal
expenses, which could have an adverse impact on our business, financial condition, results of </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-35</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=37,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=889205,FOLIO='S-35',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_36"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>operations
and prospects and the value of our common stock. Likewise, even an investigation by U.S. or foreign authorities of potential violations of the FCPA other anti-corruption laws or Trade
Control laws could have an adverse impact on our reputation, business, financial condition, results of operations and prospects and the value of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to This Offering  </B></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our management will have broad discretion over the actual amounts and timing of the expenditures of the
proceeds we receive in this offering and might not apply the proceeds in ways that enhance our operating results or increase the value of your investment.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We intend to use the net proceeds from this offering to fund ongoing and future clinical development of ALIS for patients with refractory NTM
lung disease caused by MAC and our efforts to obtain potential regulatory approvals for, and, if approved, commercialize ALIS in its approved indication; invest in increased third-party manufacturing
capacity for and commercial inventory production of ALIS in anticipation of possible commercial launch, initially in the United States and subsequently in Japan and other countries; fund further
clinical development of INS1007; and fund working capital, potential debt repayment, capital expenditures, general research and development, and for other general corporate purposes, which may include
the acquisition or in-license of additional compounds, product candidates, technology or businesses. This expected use of the net proceeds from this offering represents our intentions based upon our
current plans and business conditions. The amounts and timing of our actual expenditures may vary significantly depending on numerous factors, including the success of our clinical development efforts
and any potential commercialization efforts, as well as any strategic transactions that we may enter into with third parties, and any unforeseen cash needs. Because of the number and variability of
factors that will determine our use of the proceeds from this offering, their ultimate use may vary substantially from their currently intended use. As a result, our management will retain broad
discretion over the allocation of the net proceeds from this offering and could spend the proceeds in ways that do not necessarily improve our financial condition or operating results or enhance the
value of our common stock and your investment therein. Additionally, until the net proceeds we receive are used, they may be placed in investments that do not produce income or that lose value. See
"Use of Proceeds" for additional information. </FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the
book value of your shares.  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The public offering price of our common stock is substantially higher than the net tangible book value per share of our common stock as of
June&nbsp;30, 2017. Therefore, if you purchase shares of our common stock in this offering, you will pay a price per share that substantially exceeds our net tangible book value per share
immediately after this offering. After giving effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in this offering at the public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share and based on
our net tangible book value as of June&nbsp;30, 2017 of $0.40 per share, if you purchase shares of common stock in this offering, you will suffer substantial and immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share in the net tangible book value of the common stock. Further dilution of your investment will result from, among other things, the future exercise of outstanding
options and
vesting of restricted stock units. See "Dilution" for a more detailed description of the dilution investors purchasing shares of our common stock in the offering will incur. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-36</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=38,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=256338,FOLIO='S-36',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<A NAME="page_de49701_1_37"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


A significant portion of our total outstanding shares may be sold into the market at any time, which could
cause the market price of our common stock to drop significantly, even if our business is doing well.  </I></B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public market could occur at any time. Such sales, or the perception in the
market that the holders of a large number of such shares intend to sell, could reduce the market price of our common stock significantly. Upon the completion of this offering, we and our executive
officers and directors will be subject to lock-up agreements with the managers of the underwriters that prohibit us and such executive officers and directors, subject to certain exceptions or receipt
of the prior written consent of the managers, from disposing or pledging, or hedging against, our common stock or securities convertible into or exchangeable for shares of our common stock for a
period of 90 days, with respect to us, and 60 days with respect to our executive officers and directors, after the date of this prospectus supplement. However, all of the shares sold in this offering
and the remaining shares of our common stock outstanding immediately prior to this offering will not be subject to lock-up agreements with the managers of the underwriters and, except to the extent
such shares are held by our affiliates, will be freely tradable without restriction. In addition, the managers of the underwriters may, in their discretion, release the lock-up restrictions described
above at any time without notice. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-37</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=39,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=211350,FOLIO='S-37',FILE='DISK131:[17ZCP1.17ZCP49701]DE49701A.;10',USER='OALBERT',CD=';5-SEP-2017;14:30' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dg49701_1_38"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg49701_use_of_proceeds"> </A>
<A NAME="toc_dg49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We estimate that the net proceeds we will receive from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters exercise their option to purchase additional shares in full, we estimate that the net proceeds
from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us.
</FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
currently plan to use the net proceeds from this offering as follows:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fund ongoing and future clinical development of ALIS for patients with refractory NTM lung disease caused by MAC and our efforts to obtain
potential regulatory approvals for and, if approved, commercialize ALIS in its approved indication; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to invest in increased third-party manufacturing capacity for and commercial inventory production of ALIS in anticipation of possible
commercial launch, initially in the United States and subsequently in Japan and other countries; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fund further clinical development of INS1007; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fund working capital, potential debt repayment, capital expenditures, general research and development, and for other general corporate
purposes, which may include the acquisition or in-license of additional compounds, product candidates, technology or businesses. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. The amounts and timing of our actual
expenditures may vary significantly depending on numerous factors, including the success of our clinical development efforts and any potential commercialization efforts, as well as any strategic
transactions that we may enter into with third parties, and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this
offering. We have no current understandings, agreements or commitments for any material acquisitions or licenses of any compounds, product candidates, technology or businesses. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pending
our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment grade,
interest bearing instruments and U.S. government securities. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-38</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=40,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=322072,FOLIO='S-38',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_39"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg49701_dilution"> </A>
<A NAME="toc_dg49701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between
the public offering price per share of our common stock and the net tangible book value per share of our common stock immediately after this offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
historical net tangible book value as of June&nbsp;30, 2017 was $25.2&nbsp;million, or $0.40 per share of our common stock, based upon 62,376,416 shares outstanding on
June&nbsp;30, 2017. Net tangible book value per share is equal to our total tangible assets, less our total liabilities, divided by the total number of shares outstanding as of June&nbsp;30, 2017.
After reflecting the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock offered by us at the assumed public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, less underwriting discounts and commissions
and estimated offering expenses, our as-adjusted net tangible book value would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share of common stock
based upon&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares outstanding. This represents an immediate increase in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to our existing shareholders and an immediate dilution in
net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to investors purchasing shares of our common stock in this offering. The following table illustrates this calculation on a per share
basis: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="35pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per share</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net tangible book value per share as of June&nbsp;30, 2017</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>0.40</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to investors purchasing shares of our common stock in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>As-adjusted net tangible book value per share after this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to investors purchasing shares of our common stock in this offering</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
number of shares of our common stock to be outstanding immediately after this offering excludes:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 8,621,451 shares of our common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2017 at a weighted average
exercise price of $13.87 per share; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 46,914 shares of our common stock issuable pursuant to unvested restricted stock units outstanding as of June&nbsp;30, 2017 at a weighted
average grant price of $17.16; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> 4,978,554 shares of our common stock reserved for issuance under our 2017 Incentive Plan, plus any shares subject to outstanding awards as of
May&nbsp;18, 2017 under our 2015 Incentive Plan and 2013 Incentive Plan that subsequently are cancelled, terminated unearned, expired, forfeited, lapsed for any reason or are settled in cash without
the delivery of shares. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, the amounts in the table above assume no exercise by the underwriters of their option to purchase additional shares of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investors
purchasing shares of our common stock in this offering will experience further dilution upon the future exercise of outstanding options and vesting of restricted stock units
as well as when new equity awards are made and either are exercised or become vested under our 2017 Incentive Plan. Furthermore, subject to the terms of our lockup agreement with the managers of the
underwriters, as described in "Underwriting", we may choose to raise additional capital through the sale of additional securities due to market conditions or strategic considerations even if we
believe we have sufficient funds on hand for our current or future operating plans. To the extent that we raise additional capital in this manner, the issuance of such securities could result in
further dilution to investors purchasing shares of our common stock in this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-39</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=41,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=824709,FOLIO='S-39',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_40"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dg49701_underwriting"> </A>
<A NAME="toc_dg49701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  UNDERWRITING    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the terms and conditions set forth in the underwriting agreement, to be dated the date of this prospectus supplement, between us,
Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC and Leerink Partners&nbsp;LLC, as the managers of the underwriters named below and the joint book-running managers of this offering, we have agreed to
sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of shares of common stock shown opposite its name below: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="65pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD NOWRAP  VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><DIV style="border-bottom:solid #000000 1.5pt;margin-bottom:0pt;width:auto;display:inline-block;*display:inline;zoom:1;;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriter

<!-- COMMAND=ADD_SCROPPEDRULE,auto;display:inline-block;*display:inline;zoom:1; -->

</FONT>
</DIV></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=2 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2>Number of<BR>
Shares </FONT>&nbsp;</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Leerink Partners&nbsp;LLC</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Evercore Group&nbsp;L.L.C.&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Total</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0.75pt;font-size:0.75pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->

 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the shares covered by the option described below, unless and until the
option is exercised. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters have an option to buy up to an additional $37,500,000 of our common stock to cover sales by them of a greater number of shares than the total number set forth in the
table above. They may exercise that option for 30&nbsp;days from the date of this prospectus supplement. If any shares are purchased pursuant to this option, the underwriters will severally purchase
shares in the same proportion as set forth in the table above. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table shows the public offering price of the common stock being offered hereby, the underwriting discounts and commissions that we are to pay the underwriters and the
proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters' option to purchase additional shares. </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="60pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="73pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="77pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD COLSPAN=4 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Total<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;<font>


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


</FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Per Share</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>No Exercise</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>Full Exercise<BR></FONT>
</TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;



<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 </TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;border-bottom:solid #000000 1.5pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.5pt;" -->


 <font></FONT></TD>
<TD VALIGN="BOTTOM" style="line-height:0pt;font-size:1.5pt;font-family:arial;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#CCEEFF" VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Public offering price</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>

<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Underwriting discounts and commissions</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:arial;"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#CCEEFF" -->


 Proceeds to us, before expenses</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We
have agreed to reimburse the underwriters in an amount not to exceed $10,000 for expenses related to the offering's compliance with the rules of the Financial Industry Regulatory Authority. We have
agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares
sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of this prospectus. Any shares sold by the
underwriters to certain dealers may be sold at a discount of up to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share from the initial public offering price. After the initial offering of the shares, the
representatives may
change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters' right to reject any order in
whole or in part. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-40</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=42,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=378321,FOLIO='S-40',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_41"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Restrictions on Sales of Similar Securities  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with this offering, we and each of our directors and executive officers have agreed, subject to certain exceptions, that, for a
period of 90 days, with respect to us, and 60 days with respect to our executive officers and directors, after the date of this prospectus supplement, we and they will not, without the prior written
consent of Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC and Leerink Partners&nbsp;LLC, offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract
to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock beneficially owned by them or any securities so
owned convertible into or exercisable or exchangeable for common stock; or enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of
ownership of our common stock. </FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Stabilization  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may
include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are
required to purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A "covered short position" is a short position that
is not greater than the amount of additional shares for which the underwriters' option described above may be exercised. The underwriters may cover any covered short position by either exercising
their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered short position, the underwriters will consider, among other
things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above. "Naked" short sales
are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short
position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common
stock in the open market after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the
underwriters in the open market prior to the completion of the offering. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short-covering transactions. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Purchases
to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a
decline in the market price of our common stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of our common stock. As a result, the
price of the common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these
activities at any time. These transactions may be effected on the Nasdaq Global Select Market, in the over-the-counter market or otherwise. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Electronic Distribution  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A prospectus supplement and accompanying prospectus in electronic format may be made available by e-mail or on the web sites or through online
services maintained by one or more of the </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-41</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=43,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=793205,FOLIO='S-41',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_42"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>underwriters
or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a
specific number of shares of our common stock for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other
allocations. Other than the prospectus supplement and accompanying prospectus in electronic format, the information on the underwriters' web sites and any information contained in any other web site
maintained by any of the underwriters is not part of this prospectus supplement or the accompanying prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied
upon by investors. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Activities and Relationships  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales
and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and non-financial
activities and services.
Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to us and to persons and entities with relationships with us, for
which they received or will receive customary fees and expenses. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the ordinary course of their various business activities, the underwriters and their respective affiliates, officers, directors and employees may purchase, sell or hold a broad array
of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for their own account and for the accounts of their
customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of Insmed (directly, as collateral securing other obligations or otherwise) and/or
persons and entities with relationships with us. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or
publish or express independent research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short
positions in such assets, securities and instruments. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Selling Restrictions  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than in the United States, no action has been taken by us or any underwriter that would permit a public offering of the shares of common
stock offered by this prospectus supplement in any jurisdiction where action for that purpose is required. Shares of common stock offered by this prospectus supplement may not be offered or sold,
directly or indirectly, nor may this prospectus supplement or any other offering material or advertisements in connection with the offer and sale of any such shares of common stock be distributed or
published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus
supplement comes are advised to inform themselves about and to observe any restrictions relating to this offering and the distribution of this prospectus supplement. This prospectus supplement does
not constitute an offer to sell or a solicitation of an offer to buy any shares of common stock offered by this prospectus supplement in any jurisdiction in which such an offer or a solicitation is
unlawful. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


European Economic Area  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a "Relevant Member
State"), an offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-42</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=44,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=370307,FOLIO='S-42',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_43"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>Relevant
Member State of our common shares may be made at any time under the following exemptions under the Prospectus Directive:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to any legal entity which is a qualified investor as defined in the Prospectus Directive; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject to obtaining the
prior consent of the managers for any such offer; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> in any other circumstances falling within Article&nbsp;3(2) of the Prospectus Directive, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>provided
that no such offer of our common shares shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article&nbsp;3 of the Prospectus Directive. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
the purposes of this provision, the expression an "offer to public" in relation to our common shares in any Relevant Member State means the communication in any form and by any
means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an investor to decide to purchase our common shares, as the same may be varied in that
Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression "Prospectus Directive" means Directive 2003/71/EC (as amended, including by
Directive 2010/73/EU) and includes any relevant implementing measure in the Relevant Member State. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


United Kingdom  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the United Kingdom, this prospectus supplement is only addressed to and directed at qualified investors who are (i)&nbsp;investment
professionals falling within Article&nbsp;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii)&nbsp;high net worth entities and other
persons to whom it may lawfully be communicated, falling within Article&nbsp;49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as "relevant persons"). In the United
Kingdom, any investment or investment activity to which this prospectus relates is available only to relevant persons and will only be engaged with relevant persons. Any person in the United Kingdom
who is not a relevant person should not act or rely on this prospectus or any of its contents. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Hong Kong  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an
offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.&nbsp;32 of the Laws of Hong Kong) ("Companies (Winding Up and Miscellaneous
Provisions) Ordinance") or which do not constitute an offer to the public within the meaning of the Securities and Futures Ordinance (Cap.&nbsp;571 of the Laws of Hong Kong) ("Securities and Futures
Ordinance"), or (ii)&nbsp;to "professional investors" as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in
the document being a "prospectus" as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or
may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by,
the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong), other than with respect to shares which are or are intended to be disposed of only to persons outside
Hong Kong or only to "professional investors" in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-43</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=45,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=921873,FOLIO='S-43',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_44"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Singapore  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus
supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares
be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as
defined under Section&nbsp;4A of the Securities and Futures Act, Chapter&nbsp;289 of Singapore (the "SFA")) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in
Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth
in the SFA. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the
securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for six months after that corporation has acquired the shares under Section&nbsp;275 of the
SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2)&nbsp;where such transfer arises
from an offer in that corporation's securities pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is
by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32 of the Securities and Futures (Offers of Investments) (Shares and
Debentures) Regulations&nbsp;2005 of Singapore ("Regulation&nbsp;32"). </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Where
the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an accredited investor (as defined in
Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries' rights and interest (howsoever described) in
that trust shall not be transferable for six months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under
Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2)&nbsp;where such transfer arises from an offer that is made on terms that such rights or
interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each transaction (whether such amount is to be paid for in cash or by exchange of
securities or other assets), (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in
Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation&nbsp;32. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Japan  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as
amended) (the "FIEA"). The shares may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any
corporation or other entity organized under the laws of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except
pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-44</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>

<!-- ZEQ.=7,SEQ=46,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=231188,FOLIO='S-44',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<A NAME="page_dg49701_1_45"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Canada  </I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The shares may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument&nbsp;45-106 Prospectus Exemptions or subsection&nbsp;73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National
Instrument&nbsp;31-103 Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the shares must be made in accordance with an exemption from, or in a transaction not
subject to, the prospectus requirements of applicable securities laws. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any
amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of
the purchaser's province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory of these rights or consult with a
legal advisor. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant
to section&nbsp;3A.3 of National Instrument&nbsp;33-105 Underwriting Conflicts ("NI&nbsp;33-105"), the underwriters are not required to comply with the disclosure
requirements of NI&nbsp;33-105 regarding underwriter conflicts of interest in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-45</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=8,SEQ=47,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=704353,FOLIO='S-45',FILE='DISK131:[17ZCP1.17ZCP49701]DG49701A.;25',USER='OALBERT',CD=';5-SEP-2017;14:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_di49701_1_46"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A1"></A>MATERIAL UNITED STATES FEDERAL INCOME AND ESTATE TAX CONSIDERATIONS<BR>
FOR NON-U.S. HOLDERS OF SHARES OF OUR COMMON STOCK  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following discussion summarizes certain material United States federal income and estate tax considerations relating to the purchase,
ownership, and disposition of shares of our common stock by a non-U.S. holder (as defined below) that acquires our common stock in this offering and holds it as a capital asset. This discussion is
based on the tax laws of the United States, including the Code, Treasury regulations promulgated or proposed thereunder, and administrative and judicial interpretations thereof, all as in effect on
the date of this prospectus supplement. These tax laws are subject to change, possibly with retroactive effect, and subject to differing interpretations that could affect the tax consequences
described herein. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
purposes of this discussion, a "non-U.S. holder" is a beneficial owner of our common stock that, for United States federal income tax purposes,
is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a non-resident alien; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a foreign corporation (or other entity taxable as a corporation); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> an estate the income of which is not subject to United States federal income taxation regardless of its source; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a trust that does not have in effect a valid election under the Treasury regulations to be treated as a United States person and either
(1)&nbsp;no court within the United States is able to exercise primary supervision over the trust's administration or (2)&nbsp;no United States person has the authority to control all substantial
decisions of that trust. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
discussion does not address all aspects of United States federal income and estate taxation that may be applicable to non-U.S. holders in light of their particular circumstances or
status (including, for example, financial institutions, broker-dealers, insurance companies, partnerships or other pass-through entities, certain United States expatriates, tax-exempt organizations,
pension plans, persons in special situations, such as those that have elected to mark securities to market or that hold shares of our common stock as part of a straddle, hedge or other integrated
investment, and foreign governments or agencies). </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
a partnership (including any entity or arrangement treated as a partnership for United States federal income tax purposes) purchases, owns, or disposes of our common stock, the tax
treatment of a person treated as a partner in the partnership for United States federal income tax purposes generally will depend on the status of the partner and the activities of the partnership.
Partnerships (and other entities or arrangements so treated for United States federal income tax purposes) and their partners should consult their own tax advisors. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B><I>This discussion addresses only non-U.S. holders and does not discuss any tax considerations other than United States federal income tax and certain United States
federal estate tax considerations. Prospective investors are urged to consult their own tax advisors regarding the United States federal, state, and local, and foreign tax consequences of the
purchase,
ownership, and disposition of our common stock, including the effect of any applicable income or estate tax treaty.</I></B></FONT></P>


<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid cash dividends on our common stock. We anticipate that we will retain all earnings, if any, to support our
operations and to finance the growth and development of our business for the foreseeable future. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-46</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=48,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=333729,FOLIO='S-46',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<A NAME="page_di49701_1_47"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
we do make a distribution of cash or property with respect to our common stock, any such distribution generally will constitute a dividend for United States federal income tax
purposes to the extent of our current or accumulated earnings and profits, as determined under United States federal income tax principles. Any distribution in excess of our current or accumulated
earnings and profits will be treated, first, as a tax-free return of the non-U.S. holder's capital, up to the holder's adjusted tax basis in shares of our common stock, and thereafter, as capital gain
subject to the tax treatment described below in "Gain on Sale, Exchange or Other Taxable Disposition". </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
dividends paid to a non-U.S. holder generally will be subject to withholding tax at a 30% rate or at a lower rate under an applicable income tax treaty between the United States and
the non-U.S. holder's country of residence. In order to receive a reduced treaty withholding tax rate and to avoid backup withholding, as described below, a non-U.S. holder must furnish to us or our
paying agent a properly executed Internal Revenue Service Form&nbsp;W-8BEN or Form&nbsp;W-8BEN-E (or other applicable form) prior to payment of the dividend, certifying under penalties of perjury
that the non-U.S. holder is entitled to a reduction in withholding under an applicable income tax treaty. A non-U.S. holder that holds our common stock through a financial institution or other agent
will be required to provide appropriate documentation to the financial institution or other agent, which then will be required to provide certification to us or our paying agent either directly or
through other intermediaries. A non-U.S. holder that is eligible for a reduced rate of withholding tax pursuant to an income tax treaty may obtain a refund of any excess amounts withheld by filing a
refund claim with the Internal Revenue Service. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A
non-U.S. holder is exempt from the withholding tax described above if the dividend is "effectively connected" with the conduct of a trade or business in the United States of the
non-U.S. holder (and, if an applicable income tax treaty so provides, attributable to a permanent establishment or fixed base maintained by the non-U.S. holder in the United States) and the non-U.S.
holder
furnishes to us or our paying agent an Internal Revenue Service Form&nbsp;W-8ECI (or applicable successor form), certifying under penalties of perjury that the dividend is effectively connected with
the non-U.S. holder's conduct of a trade or business in the United States (and, if an applicable income tax treaty so provides, attributable to a permanent establishment or fixed base maintained in
the United States). "Effectively connected" dividends will generally be subject to United States federal income tax at the graduated rates that also apply to U.S. persons. A corporate non-U.S. holder
may, under certain circumstances, be subject to an additional branch profits tax at a 30% rate (or at a lower rate under an applicable income tax treaty) with respect to its "effectively connected"
dividends. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Gain on Sale, Exchange or Other Taxable Disposition  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the discussion below under "FATCA Withholding" and "Information Reporting and Backup Withholding", a non-U.S. holder generally will
not be subject to United States federal income tax or withholding tax on gain realized upon a sale, exchange or other taxable disposition of shares of our common stock (including a redemption, but
only if the redemption would be treated as a sale or exchange rather than a distribution for United States federal income tax purposes) unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the gain is "effectively connected" with the conduct of a trade or business of the non-U.S. holder in the United States (and, if required by an
applicable income tax treaty, the gain is attributable to a permanent establishment or fixed base maintained in the United States), in which case the non-U.S. holder generally will be subject to
United States federal income tax on a net income basis with respect to such gain in the same manner as if such holder were a resident of the United States and, if the non-U.S. holder is a corporation
for United States federal income tax purposes, will be subject to an additional "branch profits tax" at a 30% rate (or at a lower rate under an applicable income tax treaty); </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-47</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=49,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=933704,FOLIO='S-47',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<A NAME="page_di49701_1_48"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the non-U.S. holder is an individual who is present in the United States for 183 or more days in the taxable year of the disposition and meets
certain other conditions, in which case the non-U.S. holder generally will be subject to United States federal income tax at a 30% rate (or at a lower rate under an applicable income tax treaty) on
the gain derived from the sale, which gain may be offset by U.S.-source capital losses for the year; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> we are or have been a "United States real property holding corporation" ("USRPHC") at any time within the shorter of the five-year period
preceding the disposition and the non-U.S. holder's holding period for our common stock (the "relevant period") and the non-U.S. holder (i)&nbsp;disposes of our common stock during a calendar year
when our common stock is no longer regularly traded on an established securities market or (ii)&nbsp;owned (directly, indirectly, and constructively) more than 5% of our common stock at any time
during the relevant period, in which case such a non-U.S. holder will be subject to tax on the gain on the disposition of shares of our common stock generally as if the gain were effectively connected
with the conduct of a trade or business in the United States, except that the "branch profits tax" will not apply. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
believe we currently are not, and we do not anticipate becoming, a USRPHC for United States federal income tax purposes. Generally, a corporation is a USRPHC only if the fair market
value of its United States real property interests (as defined in the Code) equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests and its other assets used
or held for use in a trade or business. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


FATCA Withholding  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sections&nbsp;1471 through 1474 of the Code (commonly referred to as the Foreign Account Tax Compliance Act ("FATCA")) impose a 30%
withholding tax on dividends on our common stock and gross proceeds from the sale or other disposition of our common stock on or after January&nbsp;1, 2019 to a foreign entity
unless:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the foreign entity (i)&nbsp;is a "foreign financial institution" that undertakes specified due diligence, reporting, withholding and
certification obligations or (ii)&nbsp;in the case of a foreign financial institution that is a resident in a jurisdiction that has entered into an intergovernmental agreement with the United States
relating to FATCA, complies with the diligence and reporting requirements of the intergovernmental agreement and local implementing rules; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the foreign entity is not a "foreign financial institution" and identifies certain of its United States investors; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the foreign entity otherwise is exempted from withholding. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>An
intergovernmental agreement between the United States and an applicable foreign country where a foreign entity is a resident may modify the requirements under FATCA in this paragraph and, under
certain circumstances, can eliminate FATCA withholding tax. Under certain circumstances, a non-U.S. holder will be eligible for refunds or credits of withholding taxes imposed under FATCA by filing a
United States federal income tax return. Prospective investors should consult their tax advisors regarding the effect of FATCA on their ownership and disposition of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Information Reporting and Backup Withholding  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as described below, a non-U.S. holder generally will be exempt from backup withholding and information reporting requirements with
respect to dividend payments and the payment of the proceeds from the sale of shares or our common stock effected at a United States </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-48</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=50,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=222398,FOLIO='S-48',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<A NAME="page_di49701_1_49"> </A>


<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>office
of a broker, as long as the payor or broker does not have actual knowledge or reason to know that the holder is a United States person and has furnished to the payor or
broker:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a valid Internal Revenue Service Form&nbsp;W-8BEN or Form&nbsp;W-8BEN-E on which the non-U.S. holder certifies, under penalties of perjury,
that it is a non-United States person; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> other documentation upon which it may rely to treat the payments as made to a non-United States person in accordance with Treasury regulations, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>or
the non-U.S. holder otherwise establishes an exemption. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;However,
we must report annually to the Internal Revenue Service and to non-U.S. holders the amount of dividends paid to non-U.S. holders and the tax withheld with respect to such
dividends, regardless of whether withholding was required. Copies of the information returns reporting such dividends and withholding may also be made available to the tax authorities in the country
in which the respective non-U.S. holder resides under the provisions of an applicable income tax treaty. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Payment
of the proceeds from the sale of our common stock effected at a foreign office of a broker generally will not be subject to information reporting or backup withholding. However,
a sale of our common stock by a non-U.S. holder that is effected at a foreign office of a broker will be subject to information reporting and backup withholding
if:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the proceeds are transferred to an account maintained by the non-U.S. holder in the United States; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the payment of proceeds or the confirmation of the sale is mailed to the non-U.S. holder at a United States address; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the sale has some other specified connection with the United States as provided in the Treasury regulations, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>unless
the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or the non-U.S. holder otherwise
establishes an exemption. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, a sale of shares of our common stock will be subject to information reporting if it is effected at a foreign office of a broker that
is:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a United States person; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a "controlled foreign corporation" for United States federal income tax purposes; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a foreign person 50% or more of whose gross income is effectively connected with the conduct of a United States trade or business for a
specified three-year period; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> a foreign partnership, if at any time during its tax year (a)&nbsp;one or more of its partners are "U.S. persons", as defined in the Treasury
regulations, who in the aggregate hold more than 50% of the income or capital interest in the partnership, or (b)&nbsp;such foreign partnership is engaged in the conduct of a trade or business in
the United States, </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>unless
the broker does not have actual knowledge or reason to know that the holder is a United States person and the documentation requirements described above are met or an exemption is otherwise
established. Backup withholding will apply if the sale is subject to information reporting and the broker has actual knowledge that the holder is a United States person. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Backup
withholding is not an additional tax. A non-U.S. holder generally may obtain a refund of any amounts withheld under the backup withholding rules that exceed the non-U.S. holder's
income tax liability by filing a refund claim with the Internal Revenue Service. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-49</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=51,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=291846,FOLIO='S-49',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<A NAME="page_di49701_1_50"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Federal Estate Taxes  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The estates of nonresident alien decedents generally are subject to United States federal estate tax on property with a United States situs.
Because we are a United States corporation, our common stock will be United States situs property and therefore will be included in the taxable estate of a nonresident alien decedent at the time of
the decedent's death, unless an applicable estate tax treaty between the United States and the decedent's country of residence provides otherwise. An estate tax credit is available to reduce the net
tax liability of a nonresident alien's estate, but the estate tax credit for a nonresident alien is generally much smaller than the applicable credit for computing the estate tax of a United States
resident. Nonresident aliens should consult their personal tax advisors regarding the United States federal estate tax consequences of owning our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-50</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=52,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=167943,FOLIO='S-50',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<A NAME="page_di49701_1_51"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A2"></A>LEGAL MATTERS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain legal matters in connection with this offering will be passed upon for us by Covington&nbsp;&amp; Burling&nbsp;LLP, Washington, D.C.
The validity of the common stock being offered hereby will be passed upon for us by Hunton&nbsp;&amp; Williams&nbsp;LLP, Richmond, Virginia. Ropes&nbsp;&amp; Gray&nbsp;LLP, Boston, Massachusetts, is
counsel for the underwriters in connection with this offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B> <A NAME="A3"></A>EXPERTS  </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated statements included in our Annual
Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016, as set forth in their
reports, which are incorporated herein by reference. Our financial statements are incorporated by reference in reliance on Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as
experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="di49701_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_di49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information to you
by referring to those publicly available documents. The information that we incorporate by reference is considered to be part of this prospectus supplement. We incorporate by reference the documents
listed below (File No.&nbsp;000-30739) and any future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or
the portions of those documents not deemed to be filed) between the date of this prospectus supplement and the date this offering is terminated:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Quarterly Reports on Form&nbsp;10-Q for the quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Current Reports on Form&nbsp;8-K, filed with the SEC on May&nbsp;19, 2017 and May&nbsp;22, 2017; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Description of our common stock contained in our registration statement on Form&nbsp;8-A, dated June&nbsp;1, 2000, including any amendment
or report subsequently filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may access our annual report on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K, proxy statement, and other information, if any, we file
with or furnish to the SEC free of charge at the SEC's website (www.sec.gov) or our website (www.insmed.com) as soon as reasonably practicable after such material is electronically filed with, or
furnished to, the SEC. The information contained in, or that can be accessed through, our website is not part of this prospectus supplement. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may also request a copy of our SEC filings at no cost, by telephoning or writing us at the following telephone number or address: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Insmed
Incorporated<BR>
10 Finderne Avenue, Building 10<BR>
Bridgewater, New Jersey 08807<BR>
Attention: Christine Pellizzari, General Counsel and Corporate Secretary<BR>
(908)&nbsp;977-9900 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>S-51</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=53,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=333239,FOLIO='S-51',FILE='DISK131:[17ZCP1.17ZCP49701]DI49701A.;13',USER='WWASSER',CD=';5-SEP-2017;14:29' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><B>
<IMG SRC="g883363.jpg" ALT="LOGO" WIDTH="247" HEIGHT="87">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>Common Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may from time to time offer to sell common stock in amounts, at prices and on terms described in one or more supplements to this prospectus.
This prospectus describes some of the general terms that may apply to an offering of our common stock. Each time we sell common stock pursuant to this prospectus, the specific terms and any other
information relating to a specific offering will be set forth in a post-effective amendment to the registration statement of which this prospectus is a part, in a prospectus supplement or in one or
more documents incorporated by reference in this prospectus. The amendment, supplement or incorporated document(s), as applicable, may also add to, update or change information contained in this
prospectus. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock may be offered and sold in the same offering or in separate offerings to or through one or more underwriters, dealers, and agents, directly to purchasers, or through a
combination of these methods. The names and compensation of any underwriter, dealer or agent involved in the sale of our common stock will be described in the applicable prospectus supplement. See
"Plan of Distribution" on page 5 of this prospectus for additional information. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus, any applicable prospectus supplement and any incorporated documents carefully before you invest in our common stock. This prospectus is not an offer to
sell our common stock, and it is not soliciting an offer to buy our common stock, in any state or other jurisdiction where the offer or sale is not permitted. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is listed on The Nasdaq Global Select Market under the symbol "INSM." On May&nbsp;17, 2017, the last reported sale price for our common stock was $17.16. You are
encouraged to obtain current market prices for shares of our common stock. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 10 Finderne Avenue, Building 10, Bridgewater, NJ&nbsp;08807, and our telephone number is (908)&nbsp;977-9900. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="19%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=2>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors incorporated in this prospectus by reference and
described under the heading "Risk Factors" on page 2 of this prospectus.</I></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Neither the Securities and Exchange Commission ("SEC") nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>
 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p><p align=center style="font-family:arial;"><font> </FONT> <FONT SIZE=2>
The date of this prospectus is May&nbsp;19, 2017. </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=54,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=832995,FOLIO='blank',FILE='DISK131:[17ZCP1.17ZCP49701]DO49701A.;6',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_dq49701_1_1"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq49701_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>
<A NAME="DQ49701_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:arial;"></TD>
<TD WIDTH="11pt" style="font-family:arial;"></TD>
<TD WIDTH="12pt" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#dq49701_about_this_prospectus"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#dq49701_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_insmed_incorporated"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INSMED INCORPORATED</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_insmed_incorporated"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_risk_factors"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_risk_factors"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_note_regarding_forward-looking_statements"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_note_regarding_forward-looking_statements"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_use_of_proceeds"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_use_of_proceeds"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_description_of_common_stock"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_description_of_common_stock"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_plan_of_distribution"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_plan_of_distribution"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_legal_matters"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_legal_matters"><FONT SIZE=2>6</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_experts"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_experts"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_where_you_can_find_more_information"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_where_you_can_find_more_information"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:arial;"><A HREF="#ds49701_incorporation_by_reference"><p style="font-family:arial;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:arial;"><A HREF="#ds49701_incorporation_by_reference"><FONT SIZE=2>7</FONT></A></TD>
<TD style="font-family:arial;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="dq49701_about_this_prospectus"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>This prospectus is part of a registration statement that we filed with the SEC, utilizing a "shelf" registration
process as a "well-known seasoned issuer," as defined in Rule&nbsp;405 under the Securities Act. Under this shelf registration process, we may offer and sell from time to time in one or more
offerings the common stock described in this prospectus.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>This prospectus provides you with a general description of our common stock. Each time we sell shares of our common stock, we will provide a prospectus
supplement that will contain specific information about the terms of that offering. The prospectus supplement, or information incorporated by reference in this prospectus or any prospectus supplement
that is of a more recent date, may also add to, update or change information contained in this prospectus. To the extent that any statement that we make in a prospectus supplement or incorporate by
reference from a future SEC filing is inconsistent with statements made in this prospectus, the statements made in this prospectus will be deemed modified or superseded by those made in the prospectus
supplement or such incorporated document. This prospectus may not be used to consummate a sale of our common stock unless it is accompanied by a prospectus supplement. We may also authorize one or
more free writing prospectuses to be provided to you that may contain material information relating to an offering of our common stock. You should carefully read this prospectus, any applicable
prospectus supplement and any relevant free writing prospectus, together with the information incorporated herein by reference, prior to making any decision regarding an investment in our common
stock.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>You should rely only on the information contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free
writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. We are not making offers to sell or seeking offers to buy shares of our common
stock in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus, any prospectus supplement, the documents incorporated by
reference and any related free writing prospectus is accurate only as of the respective dates of such documents. Our business, financial condition, results of operations and prospects may have changed
materially since those dates.</B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><B>Unless the context otherwise indicates, references in this prospectus to "Insmed", the "Company", "we", "us" and "our" refer to Insmed Incorporated, a Virginia
corporation, together with its consolidated subsidiaries. Insmed and ARIKAYCE are trademarks of Insmed Incorporated. Our logos and trademarks are the property of Insmed. All other brand names or
trademarks appearing in this prospectus are the property of their respective holders. Use or display by us of other parties' trademarks or trade dress in this prospectus is not intended to, and does
not, imply a relationship with, or endorsements or sponsorship of, us by the trademark or trade dress owners.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=55,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=112715,FOLIO='1',FILE='DISK131:[17ZCP1.17ZCP49701]DQ49701A.;6',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2><A
NAME="page_ds49701_1_2"> </A>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_insmed_incorporated"> </A>
<A NAME="toc_ds49701_1"> </A>
<BR></FONT><FONT SIZE=2><B>  INSMED INCORPORATED    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. We were incorporated in the Commonwealth
of Virginia on November&nbsp;29, 1999. On December&nbsp;1, 2010, we completed a business combination with Transave,&nbsp;Inc., a privately held New Jersey based company focused on the
development of differentiated and innovative inhaled pharmaceuticals for the site specific treatment of serious lung diseases. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation, which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria
lung disease caused by </FONT><FONT SIZE=2><I>Mycobacterium avium</I></FONT><FONT SIZE=2> complex, a rare and often chronic infection that is capable of causing irreversible lung damage and can be
fatal. Our earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is a novel oral, reversible inhibitor of dipeptidyl peptidase&nbsp;1, an enzyme responsible for activating neutrophil
serine proteases, which are implicated in the pathology
of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product
profile for rare pulmonary disorders, including pulmonary arterial hypertension. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
principal executive offices are located at 10 Finderne Avenue, Building 10, Bridgewater, NJ&nbsp;08807, and our telephone number is (908)&nbsp;977-9900. Our Internet address is
www.insmed.com. The information on our web site is not incorporated by reference into this prospectus or any applicable prospectus supplement and should not be considered to be part of this prospectus
or any applicable supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_risk_factors"> </A>
<A NAME="toc_ds49701_2"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An investment in our common stock involves risks. Prior to making a decision about investing in our common stock, you should carefully consider
the specific risks discussed under "Risk Factors" in our Annual Report on Form&nbsp;10-K for our most recent fiscal year, as updated by our Quarterly Reports on Form&nbsp;10-Q and other SEC
filings subsequent thereto, pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and in any applicable prospectus supplement.
The risks and uncertainties described in any applicable prospectus supplement and in our SEC filings are not the only ones facing us. Each of these risks could materially and adversely affect our
business, results of operations and financial condition, resulting in a decline in the trading price of our common stock and a complete or partial loss of your investment. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_ds49701_3"> </A>
<BR></FONT><FONT SIZE=2><B>  NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains, and the information incorporated by reference herein and any applicable prospectus supplement may contain,
forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Exchange Act. "Forward looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words such as "may," "will," "should," "could," "would,"
"expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing
future events, conditions or circumstances) identify forward looking statements. </FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward
looking statements are based on our current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause our actual results,
performance and achievements and the timing of certain events to differ materially from the results, </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=56,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=455220,FOLIO='2',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_3"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>performance,
achievements or timing discussed, projected, anticipated or indicated in any forward looking statements. Such factors include, among others, the
following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the research and development of our existing product candidates, including due to delays in patient enrollment or failure of
our preclinical studies or clinical trials to satisfy pre-established endpoints; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to develop, or to license for development, additional product candidates, including a failure to attract experienced third party
collaborators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain, or delays in obtaining, regulatory approval from the United States Food and Drug Administration, the European Medicines
Agency, and other regulatory authorities for our product candidates or their delivery devices, including due to insufficient clinical data or selection of endpoints that are not satisfactory to
regulators; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure of third parties on which we are dependent to conduct our clinical trials and to manufacture sufficient quantities of our product
candidates for clinical or commercial needs; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to comply with license agreements that are critical for our product development, including our license agreements with PARI
Pharma&nbsp;GmbH and AstraZeneca AB; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> lack of safety and efficacy of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inaccuracies in our estimate of the size of the potential markets for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to maintain regulatory approval for our product candidates, once received, due to a failure to satisfy post-approval regulatory
requirements, such as the need for post-clinical trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the rate and degree of market acceptance of product candidates, if approved; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> uncertainties in the timing, scope and rate of reimbursement for our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> competitive developments affecting our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inaccurate estimates regarding our future capital requirements, including those necessary to fund milestone payments or royalties owed to third
parties; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to repay our existing indebtedness or to obtain additional financing when needed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to obtain, protect and enforce our patents and other intellectual property; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> inability to create an effective direct sales and marketing infrastructure or to partner with a third party that offers such an infrastructure
for distribution of our product candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> the cost and potential reputational damage resulting from litigation to which we are a party, including, without limitation, the class action
lawsuit pending against us; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> failure to comply with the laws and regulations that impact our business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> loss of key personnel; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> changes in laws and regulations applicable to our business, including those related to pricing and reimbursement of our product candidates. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
factors, risks and uncertainties referred to above and others are more fully described under the heading "Risk Factors" in our Annual Report on Form&nbsp;10-K for the fiscal year
ended December&nbsp;31, 2016, as updated from time to time in our Quarterly Reports on Form&nbsp;10-Q and other SEC filings subsequent thereto, including any applicable prospectus supplement. We
caution readers not to place undue reliance on any such forward-looking statements, which speak only as </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=57,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=586443,FOLIO='3',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_4"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>of
the date they were made. We disclaim any obligation, except as specifically required by law, and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our
expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in such
forward-looking statements. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should read this prospectus, the registration statement of which this prospectus forms&nbsp;a part, the documents incorporated by reference herein, and any applicable prospectus
supplement in their entirety and with the understanding that our actual future results may be materially different from those expressed in forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_use_of_proceeds"> </A>
<A NAME="toc_ds49701_4"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We will retain broad discretion over the use of the net proceeds from the sale of our common stock offered under this prospectus. Unless we
indicate otherwise in the applicable prospectus supplement, we anticipate that any net proceeds will be used for working capital and general corporate purposes. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_description_of_common_stock"> </A>
<A NAME="toc_ds49701_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following is a summary of the material terms of our common stock, which is based upon, and is qualified in its entirety by reference to,
our Articles of Incorporation, as amended (the "Articles of Incorporation"), our Amended and Restated Bylaws (the "Bylaws") and applicable provisions of the Virginia Stock Corporation Act ("VSCA").
This summary may not contain all the information that is important to you; you can obtain additional information regarding our Articles of Incorporation and Bylaws by referring to such documents,
copies of which are included as exhibits to the registration statement of which this prospectus forms&nbsp;a part. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Under our Articles of Incorporation, we have authority to issue 500,000,000 shares of common stock, par value $0.01 per share. As of
May&nbsp;17, 2017, there were 62,166,716 shares of common stock issued and outstanding. All shares of common stock will, when issued pursuant to this prospectus, be duly authorized, fully paid and
nonassessable. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividend Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject to the rights of the holders of any of our preferred stock then outstanding, the holders of our common stock are entitled to receive
ratably such dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. As of the date of this prospectus, we have not declared or paid any
dividends on our shares of common stock, and there were no shares of preferred stock outstanding, although our board of directors is authorized to issue preferred stock with rights senior to those of
the common stock without any further vote or action by the holders of our common stock. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rights Upon Liquidation  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event we are liquidated, dissolved or our affairs are wound up, after we pay or make adequate provision for all of our known debts and
liabilities, each holder of common stock will receive distributions pro rata out of assets that we can legally use to pay distributions, subject to the rights of the holders of any of our preferred
stock then outstanding. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=58,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=237499,FOLIO='4',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_5"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock are entitled to one vote per share and will have the exclusive power to vote on all matters presented to our
shareholders, including the election of directors, except as otherwise provided by the VSCA and subject to the rights of the holders of any of our preferred stock then outstanding. An election of
directors by our shareholders will be determined by a plurality of the votes cast by the shareholders entitled to vote on the election, although we have recently adopted a director resignation policy
applicable to director nominees in uncontested elections. Our Articles of Incorporation do not provide for cumulative voting. In accordance with our Articles of Incorporation, our board is divided
into three classes serving staggered three-year terms, with one class being elected each year at our annual meeting of shareholders. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Subject
to certain exceptions set forth in the VSCA, matters other than the election of directors generally will be approved if the votes cast by our shareholders favoring the action
exceed the votes cast opposing the action. Subject to the rights of the holders of any of our preferred stock then outstanding, however, the affirmative vote of at least 75% of the voting power of the
outstanding shares of our capital stock entitled to vote generally in the election of directors, voting together as a single group, will be required to take the following
actions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> remove a director, which may only be done for cause; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> alter, amend, repeal, or adopt any provision inconsistent with, the provisions of (1)&nbsp;our Articles of Incorporation that provide for a
classified board, director removal only for cause, filling of newly created or vacant directorships, or bylaw amendments or (2)&nbsp;our Bylaws. </FONT></DD></DL>
</UL>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Other Rights  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Holders of our common stock will have no preference, appraisal or exchange rights, except for any appraisal rights provided by the VSCA.
Furthermore, holders of our common stock have no conversion, sinking fund or redemption rights, or preemptive rights to subscribe for any of our securities. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Transfer Agent and Registrar  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The transfer agent and registrar for our common stock is Broadridge Investor Communication Solutions,&nbsp;Inc. Its address is 1717 Arch
Street, Suite&nbsp;1300, Philadelphia, PA 19103. </FONT></P>

<P style="font-family:arial;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Listing  </I></B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our common stock is listed on the Nasdaq Global Select Market under the symbol "INSM." </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_plan_of_distribution"> </A>
<A NAME="toc_ds49701_6"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the common stock registered pursuant to this prospectus in the following ways:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to or through underwriters; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> to or through dealers; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> through agents; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> directly to purchasers; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> through a combination of any of the foregoing methods. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
reserve the right to sell directly to or exchange our common stock directly with investors on our own behalf in those jurisdictions where we are authorized to do so. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=59,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=286328,FOLIO='5',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_6"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may distribute such common stock from time to time in one or more transactions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at a fixed price or prices, which may be changed from time to time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at prices related to such prevailing market prices; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> at negotiated prices. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We,
or the purchasers of the common stock for whom the underwriters may act as agents, may compensate underwriters in the form of underwriting discounts or commissions, in connection
with the sale of the common stock. Underwriters may sell our common stock to or through dealers, and those dealers may receive compensation in the form of discounts, concessions or commissions from
the underwriters and/or commissions from the purchasers for whom they may act as agents. Unless otherwise indicated in the applicable prospectus supplement, an agent will be acting on a best efforts
basis and a dealer will purchase our common stock as a principal and may then resell such common stock at varying prices to be determined by the dealer. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will name any underwriter, dealer or agent involved in the offer and sale of common stock in the applicable prospectus supplement. In addition, we will describe in the applicable
prospectus supplement the public offering or purchase price and the proceeds we will receive from the sale of our common stock, any compensation we will pay to underwriters, dealers or agents in
connection with such offering of our common stock, any discounts, concessions or commissions allowed or re-allowed by underwriters to participating dealers, and any exchanges on which our common stock
will be listed. Dealers and agents participating in the distribution of the common stock may be deemed to be underwriters, and any discounts and commissions received by them and any profit realized by
them on resale of the common stock may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters, dealers and agents against certain civil
liabilities, including liabilities under the Securities Act, and to reimburse these persons for certain expenses. We may also agree to contribute to payments that the underwriters, dealers or agents
or any of their controlling persons may be required to make in respect of such liabilities. We may grant underwriters who participate in the distribution of the common stock we are registering
pursuant to this prospectus an option to purchase additional shares in connection with a subsequent distribution. Certain underwriters, dealers or agents and their associates may engage in
transactions with and perform services for us in the ordinary course of our business. </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
facilitate the offering of our common stock, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of our
common stock. Such transactions may include over-allotments or short sales of our common stock, which involve the sale by persons participating in the offering of more common stock than we sold to
them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market or by exercising their option to purchase additional shares, if
any. In addition, these persons may stabilize or maintain the price of our common stock by bidding for or purchasing such common stock in the open market or by imposing penalty bids, whereby selling
concessions allowed to dealers participating in the offering may be reclaimed if the common stock sold by them is repurchased in connection with stabilization transactions. Should these transactions
be undertaken, they may be discontinued at any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_legal_matters"> </A>
<A NAME="toc_ds49701_7"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless the applicable prospectus supplement indicates otherwise, the validity of the common stock being offered by this prospectus will be
passed upon for us by Covington&nbsp;&amp; Burling&nbsp;LLP, Washington,&nbsp;D.C. and/or Hunton&nbsp;&amp; Williams&nbsp;LLP, Richmond, Virginia. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=60,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=723689,FOLIO='6',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_7"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_experts"> </A>
<A NAME="toc_ds49701_8"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ernst&nbsp;&amp; Young&nbsp;LLP, independent registered public accounting firm, has audited our consolidated financial statements included in
our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016, and the effectiveness of our internal control over financial reporting as of December&nbsp;31, 2016, as set forth
in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on
Ernst&nbsp;&amp; Young&nbsp;LLP's reports, given on their authority as experts in accounting and auditing. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_where_you_can_find_more_information"> </A>
<A NAME="toc_ds49701_9"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document we file
at the SEC's Public Reference Room at 100&nbsp;F&nbsp;Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC
filings are also available to the public from the SEC's website at www.sec.gov. We maintain a website at www.insmed.com. The information contained in, or that can be accessed through, our website is
not part of this prospectus. We have filed with the SEC a registration statement under the Securities Act with respect to the common stock registered pursuant hereto. This prospectus omits some
information contained in the registration statement in accordance with SEC rules and regulations. For further information with respect to us and the common stock registered pursuant to this
prospectus, you should review the registration statement, the applicable prospectus supplement, the information incorporated herein and therein, and the exhibits included herein and therein. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><A
NAME="ds49701_incorporation_by_reference"> </A>
<A NAME="toc_ds49701_10"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" the information we file with it, which means that we can disclose important information to you
by referring to those publicly available documents. The information that we incorporate by reference is considered to be part of this prospectus. We incorporate by reference the documents listed below
(File No.&nbsp;000-30739) and any future filings we make with the SEC under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (in each case, other than those documents or the portions of
those documents not deemed to be filed) between the date of this registration statement and, in the case of any particular offering of our common stock, the date such offering is
terminated:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2016; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Quarterly Report on Form&nbsp;10-Q for the quarter ended March&nbsp;31, 2017; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Current Report on Form&nbsp;8-K, filed with the SEC on May&nbsp;19, 2017; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:arial;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:arial;"><FONT SIZE=2> Description of our common stock contained in our registration statement on Form&nbsp;8-A, dated June&nbsp;1, 2000, including any amendment
or report subsequently filed for the purpose of updating such description. </FONT></DD></DL>
</UL>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because
we are incorporating by reference future filings with the SEC, this prospectus is continually updated and information that we subsequently file with the SEC will automatically
update and supersede the information herein to the extent inconsistent herewith. This means that it is important to review all of the SEC filings that we incorporate by reference to determine if any
of the
statements in this prospectus or in any document previously incorporated by reference has been modified or superseded. </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=61,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=903379,FOLIO='7',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<A NAME="page_ds49701_1_8"> </A>

<P style="font-family:arial;"><FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
may request a copy of our SEC filings at no cost, by telephoning or writing us at the following telephone number or address: </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>Insmed
Incorporated<BR>
10 Finderne Avenue, Building 10<BR>
Bridgewater, New Jersey 08807<BR>
Attention: Christine Pellizzari, General Counsel and Corporate Secretary<BR>
(908)&nbsp;977-9900 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=62,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=228692,FOLIO='8',FILE='DISK131:[17ZCP1.17ZCP49701]DS49701A.;5',USER='VRIVERA',CD=';5-SEP-2017;02:05' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:arial;"><FONT SIZE=2>
 </FONT> <FONT SIZE=2>


<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:arial;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.5pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.5pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg49701a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:arial;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>$250,000,000 </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4>Common Stock </FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=4><B>
<IMG SRC="g839396.jpg" ALT="LOGO" WIDTH="249" HEIGHT="88">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:arial;"><FONT SIZE=2><I>Joint Book-Running Managers  </I></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="50%" style="font-family:arial;"></TD>
<TD WIDTH="16%" style="font-family:arial;"></TD>
<TD WIDTH="33%" style="font-family:arial;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Goldman Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:arial;"><FONT SIZE=4><B>Leerink&nbsp;Partners</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2><I> Passive Book-Runner</I></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=4><B> Evercore ISI</B></FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD COLSPAN=3 ALIGN="CENTER" VALIGN="BOTTOM" style="font-family:arial;"><BR><FONT SIZE=2><I> Co-Lead Manager</I></FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD COLSPAN=3 ALIGN="CENTER" style="font-family:arial;"><BR><FONT SIZE=4><B> Stifel</B></FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>

 <p style="font-family:arial;line-height:1pt;margin-left:18pt;"><font> </FONT> <FONT SIZE=2>
<!-- BLANK LINE TO FORCE PARA -->
&nbsp;&nbsp;&nbsp;
</font></p>
 <P style="font-family:arial;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<HR NOSHADE>
<P style='font-family:arial;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=63,EFW="2233170",CP="INSMED INCORPORATED",DN="1",CHK=760147,FOLIO='blank',FILE='DISK131:[17ZCP1.17ZCP49701]HO49701A.;15',USER='DSLOAN',CD=';5-SEP-2017;14:50' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g839396.jpg
<DESCRIPTION>G839396.JPG
<TEXT>
begin 644 g839396.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@!!35),3%]'4D%02$E#4SI;24Y3345$
M7TE.0T]24$]2051%1%U)3E--141?3D]?5$%'7T1,7S1#7TQ/1T\N15!3_]L
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M"A4B87&!L2,R47*1H187.7:WP='P&20V-T)5=Y>VUB<X0U)79[*UPM?A_\0
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M/H=P@9LQ<WVX1["O0;B7<,B)KI0,6U=RLE-D352<O8]LK&L%$G[ULX0R;4\
M;]^IA<+1EAA7;;F9\2070E;_ '.<B*M1XEX ^+_!BJNK&]CX"/2C4U$DDZO2
MF:Z<.W,W^<DT5%?,+ZO[>\0R6?<YXEPK%.3L7>3;[7ZDI(IAR>*BW[KQI^8(
M':?\I$5]M*2:7)#@*S5,#%, B4>B5C'&M*P_C^HXQQW!,ZY2J/!LJ_6X9BD5
M-%G',B=I3'$I2F7>O%3*OI-\KW.9&1<NGSI11PX4.;1_4[O*IV+D(+N-QU.[
MW5EZ:1"W>5Y8\?B*DDBI&B1O%*!8LRSE4CEC$CH[V&D6&"+II3KM90J[LL$;
M$\5\%W;1.]['@ >2#H: 'DGKGE;A=K^<-KUL9T?/6.7U)FI%B:3A#.EHF<@I
MZ.24(DL\KUAAG4C"RA&2RJ2+]!LZ!]%K+()R#1H== %&2^@_O&O648/(FV7)
MMDE;:^QG"1%UQE-3SY:3FD*(Y?$KTY47,D\64>OH^JRRL*Y@#NE'+AE&SRL3
MXY8^-C&Z-P?*&:HQ>[;<(W,[=H,G6LY_,+5T=(PO4X^WT*TKR+1NL ]I&SEY
M68AR\3.4?%48M#E$IDN1C-Z"#UTVWQ3C9!44T'^W_(23Q,"D$%TVUIQTZ0*8
M3%,8H)N"@H IB01$.#"8OT=1V7RB>H/H]D,YE*56+(T5GF5X4;A!<Q]I TM4
MRM++$MFJ?;E0R/XE="[ *0J-#4OK&C,48J/.ME7'@-KP>+>0=#XWTY:_?-(Q
MD\D7[E%FQ8-7#UZ[<'!-!JT:HG<.7*ZAA I$6Z":BRIA$ *0AA$?32(>_P"Z
MC.7=YF0K)',K-.5S;Y'3+MIC_&4.[=1\=-0[)PLVC;5=V[(Y%K39+ @)9$L?
M)&=Q,$BZ;Q<3'E=(NW[]X/+U:D[GBG)E0A5%$9BU8^NE;BETETVRR,E.UF4B
MF"J3A8#(H*D=NT1365*9-(W"ARB4HAKF\1XSU LT:9W'&C;11+#''=1$RS.4
MT?9*9+MSN(N58+ 4X TF(D[*0:* !A*FLB/'/.JGZ!X?&7+6>RMBO!;R>,2B
MF.CG"M].+ MM)8C#!@DKO!'$MA5+PKS"D>ZP+C*2.HB0$JC\^9'WUQT#K6P-
MDD?!\?EU,3B3H0[R,AT^+M4_+XEPZ,PS0D&53N4I8)"UM6KI))PU&;CJA R$
M5".ED%BJ*1JDNZD6)P,UDFS)V15NG&WN5VVW7:IG2<P;DQ>L2]KJ9JC(.)2L
MJO)&OOV=FCHV=C744[EXR+D#E(W=^5<>8CVQTGS5RF0#I$364;XVQ=9;9[G6
M%AF5[NC+ >27"+=*7JF35_FFMFE% X<C6LA'(%6E(LZXB+/YT>P<R"1B%=Q*
M*A3".2L^=-G9]O-R SSU>4[-8)V4K5=AFD]0\DO(NNR\/7U7ZT.Z1"#\U&R"
MI2OUDC/T7"@KMTFZ0CVH$U)T?5?NS Y^U#ZA8ZS2QKPSK!5IXE8VCM"6(Q-6
MLRS(+=7VA*ID%J=6Y*ZLWGI#48)(U-5U9P5)9GV"NCOD #Q;>O'$:^-=6MU5
M-I^7MX.V:EXYPN6LJVB!R=6KL]:VFQ+5ED\A(^GVR%=-FS]..D4E'JCJ>9"1
MJ[(@U5;D<'4<E.FFDJGCN:V>9IVAVBOU/.],KU=E[7#OYZNGB9VN6MG*1$9(
MEBG3HCN),H=J*3LZ1"MI!!HY,FJFH1(0\0$^BNDF5%--(@"!$R$3+R/(]I"@
M0O(_$>TH<C\??2FORB'_ #Y[<O\ 9+>?^.8O4+Z)=X9:++T>SU6H<38.3ML[
M0R?6+*M5[ X3+,(PADA3:O"Y"E@""01TR-=#&]C;<UX*!O\ #HL%^-?D3\'Y
MZC7P#OCO6UG:_E/$>$7[BG9%S1DQO-V7(,<DT:/*;08"F14*BWJ3@J8*,[?9
M916227GC@(UR"CC+1?9,R35]&??HO2XW_9FJ9LMPN#)YW'V)J:P-9&^6^LUF
MYVU%VF9X23;Q-RG6UI?*R9# LS=3Y8]23!PBNDJJ@N5<<T=&#:Q7=QVZI:RW
MR':SN/\  \ SO\A#2+4CR(G;G(R8QE BY5JLFHV=L&;MI,6=PQ< 9%TO 1Z:
MZ:K8ZR1W;0(4 $O " AP;GW-R' ]WZ1$/?G5J]0/42/L//6\?VUC,=-F+S19
M#/Y&_'+*SO+'']'3 @FK2'VJB0LO*4PQ12+PC,\D\O7"K4^JB5YG<1KM(D4@
M  ?O-Y!'EM_ V2#LZ '7-CKECRKMYRD2=K<A:L39=QS/N62CA)-W 6>N3T0[
M,A(0\TR4!%5=N#A$[2:@)1-Q&RK456SQLY:KE,:87>GUALL;C,8XGQ!@Y:?Q
M^^M= K)L\250+(-;-8\D3*8Q\KC"CKL$S3C&L)O4R.5G,&O\]6569:5MLOY!
M@]"9P1UIZXTK_4+RNX9-FK1*TU/%=K6(U Q?&?/::VAGSMT42E*5XZ7KXJ+"
MGW%4("*IC>,HJ!=V>@1M4K]TMN1-U-SBDI,,9R3?'N*TGK<%FC*XR,0E+V^U
MH@<P$^=86!DH>$AU_#4%D>=FG"1DW16ZB=J[AO\ ;-GM;!^I.<P\%N[0QM6[
M0J'B5EO9.*$14I69&]^&O9D,L33(_P!+[<EJ.(R HW&%9EGEIQR%59V5F'@A
M4/EQY&B5&B 1O8&]=1Q*])WJ -\?O,G+[=II"*1CUIMW!GLE/_C&49$)XZ[@
MU#)-J6-P_P#"[ESQ1DS6)3M.3YK.[_(&U/P%GS)VV+)T#ES$4\\KUI@':*SM
MH@JNWB;;$HKIK/ZC;HY(Z*<S 3*21F;MD]*91FJ=-^P.SDV;9RCT@A*4"\<
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M6LFUC%#Y-9O#,!3+;@=MZBQ@ RRGE\IAXBQOI+*>E3  [U1.?T  ^EZ%*'
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#>O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g883363.jpg
<DESCRIPTION>G883363.JPG
<TEXT>
begin 644 g883363.jpg
M_]C_X  02D9)1@ ! 0$ V #8  #__@ \35),3%]'4D%02$E#4SI;24Y3345$
M7TE.0T]24$]2051%1%U)3E--141?2%1-3%\T0U],3T=/+D504__; $,  0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$(
M %< ]P,!(@ "$0$#$0'_Q  >   " @(# 0$             "@@)!PL#!08$
M ?_$ %$0   & 0," P0%!0L%$0    $" P0%!@< "!$)$A,A,0H4%5$6(D%A
ML2,R<H&1%Q@X.4)Q=Z&RML$95WBW\!HD)S,U-D9'5EAB=I>UT=;Q_\0 ' $
M 00# 0                ($!08! P<(_\0 0A$  @(! P,"! ,%! 4-
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M\X Z$V]G(^9Z]%9\IT/AS#L/86#V]6EU=Z?:96>@8UZV=OX"C0U4EYEP\D+
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M\#Y:[[48RLC,CJRNI*LK JRL#L593L00?!! (/@]+]_;HU^"'/[0']@@.@1
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M^'[>?LU'OKUJ@CL(?''CRS/B,//[Y:2#SXUG+HXJ@OTT]J*H#SWTFPCSZ_\
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MYO+[]-*=&'PC=.';VJD0A/''*"JHD* >(J.7;R0RAQ  $QQ A2B8?,0*4/0
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M>:M5$JV93-'5"TY9%K/4YBMV'6([1!XD,+QLQ2MXV:O&7:JDJHJR++VD?DH
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7$(8$[<8)(7DS>3[DERS$G]3_ "Z__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
